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ABSTRACT 
 
The Hand, Foot and Mouth Disease is caused by a group of Enteroviruses such 
as Enterovirus 71 (EV-A71) and Coxsackievirus CV-A6, CV-A10, and CV-A16. Mild 
symptoms of EV-A71 infection in children range from high fever, vomiting, rashes and 
ulcers in mouth, commonly affecting children and infants. EV-A71 can produce more 
severe symptoms such as brainstem and cerebellar encephalitis, leading up to 
cardiopulmonary failure and death. The lack of vaccines and antiviral drugs against EV-
A71 highlights the urgency of developing preventive and treatment agents against EV-
A71 to prevent further fatalities. The molecular basis of virulence in EV-A71 is still 
uncertain. It remains to be investigated if there is a universal molecular determinant 
present in every EV-A71 fatal strain or whether every fatal strain differs in virulence 
determinant depending on their sub-genotype. In this study, genetically modified EV-
A71 virus was constructed by substituting nucleotides at positions 158, 475, 486, and 
487 based on the neurovirulence of poliovirus Sabin strains 1, 2 and 3. The single 
nucleotide difference between the fatal strain 41 (5865/Sin/000009) and the non-fatal 
strain (strain 10) was investigated to see if it is responsible for neurovirulence by 
introducing a nucleotide substitution (Guanine) at position 5262 in the EV-A71 strain 41 
genome.  Another mutant strain was also constructed through partial deletion of the 5’-
NTR region in the EV-A71 genome. The virulence of the mutated EV-A71 strains were 
evaluated in Rhabdomyosarcoma cell culture by plaque assays, tissue culture infectious 
dose (TCID50) determinations, real time Reverse-Transcriptase Polymerase Chain 
Reaction (RT-PCR) and production of VP1. It was observed that mutants 475 and the 
partial deletant (deletion from nt. 475-485 in the 5’NTR) had minimal cytopathic effects 
as compared to mutants 158, 486, and 5262 when transfected with RD cells. This was 
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consistent with the RT-PCR results that showed the viral RNA copy number for mutants 
475, 487 and partial deletant (5’NTR) to be of lowest amount when RNA was extracted 
from transfected RD cells. The partial deletant (PD) may be the most stable mutant 
genetically as it demonstrated high immunogenicity (neutralizing titre of 1:32) and low 
pathogenicity and hence, could be a good potential LAV candidate for further studies. In 
addition, intraperitoneal administration of the heat-inactivated EV-A71 mutants 158, 
475, 486, 487, 5262 and PD and the homologous EV-A71 whole virion in the murine 
model triggered both cellular and humoral immune response. 
The data collectively indicated that every fatal EV-A71 strain differs in virulence 
determinant depending on their sub-genotype. Differences in nucleotide substitutions in 
the various mutants were reflected in the differences observed in immunogenicity based 
on the neutralizing titres of mice antisera. Hence, vaccines can be rationally designed to 
treat different EV-A71 genotypes and sub-genotypes. 
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CHAPTER 1 
LITERATURE REVIEW 
1.1 Introduction 
1.1.1  Development of vaccines against viral pathogens 
 Vaccination for various viral diseases has markedly reduced mortality and 
morbidity worldwide for more than 200 years. Indeed, the greatest public health success 
can be attributed to vaccination. Nevertheless, the future is abound with challenges as 
there remains many diseases that do not yet have effective vaccines such as HIV/AIDS, 
Ebola, Hepatitis C, and the Hand, Foot, Mouth (HFMD) disease. Every year, two new 
species of viruses are added into the list of approximately 200 different infectious 
viruses (Small and Hildegund, 2012). In addition, some viruses particularly RNA viruses 
can emerge as new pathogens as they have high mutation rates due to their error-prone 
RNA dependent RNA polymerase. The existing viruses can evolve to become more 
virulent through recombinations or mutations and the mutated strains also do not have 
any effective vaccines against them.  
Currently, there are only an estimated 15 vaccines to combat the 200 viruses 
known to infect man (Small and Hildegund, 2012). Although there are more vaccines 
undergoing clinical trials, it is worrying to note that humans remain vulnerable to the 
existing 180 or so viruses that have no effective vaccines. Therefore, increased studies 
are required in the development of new and better vaccines, whereby high efficacy, 
long-lasting immunity, minimal risk in vaccinees, safe and easy production, low cost, 
16 
 
dispensing the need for refrigeration and convenient delivery are the major goals in their 
design. 
1.2 Polio virus vaccines 
1.2.1 Inactivated polio vaccine 
Poliovirus (PV) is the etiological agent of poliomyelitis and belongs to 
Enterovirus species C within the Picornaviridae family. Poliomyelitis was a public 
health scare in the 1950s, even in countries with the best health systems and hygiene 
practises in place. This thereby led to the raising of funds to support research in the 
development of a polio vaccine. The Inactivated Polio Vaccine (IPV) was the first 
poliovirus vaccine to be licensed in 1955. IPV was developed in 1952 by Dr Jonas Salk 
and was prepared by formalin-inactivation of three wild-type virulent strains which are 
the Mahoney (type 1), MEF-1 (type 2) and Saukett (type 3) (Salk et al., 1954). The 
United States started using the IPV that had such high efficacy that other countries 
around the world started to follow suit. This initiated the global polio eradication 
worldwide (Chumakov and Ehrenfeld, 2008).  
Although IPV is considered safe, there is a risk of exposure to the wild type 
strain during the manufacturing process. Figure 1.1 shows the manufacturing process for 
the IPV. During monovalent bulk preparation, Vero cells were expanded using two pre-
culture steps and cell culture followed by virus culture. The PV was purified using 
normal flow filtration for clarification, tangential flow filtration for concentration and 
followed by two chromatography steps, involving size exclusion and ion exchange 
chromatography. Purified virus was inactivated using formaldehyde. 
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Figure 1.1: Process overview for preparation of trivalent IPV. Monovalent bulks are 
prepared for each poliovirus (type 1, 2 and 3) separately (Thomassen et al., 2013).  
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Subsequently, the IPVs were mixed to obtain trivalent bulk prior to formulation and 
filling (Thomassen et al., 2013). Due to the need to cultivate large amounts of the live 
polio virus which involved complex manufacturing and purification processes, exposure 
of workers to the live virus must be safely guarded. At the Cutter Laboratories, 
insufficient inactivation of the IPV led to paralysis in almost 200 vacinees and their 
contacts (Offit, 2005).   
This incident resulted in the temporary halt of the use of IPV and encouraged 
research groups worldwide to produce a live attenuated polio vaccine. Although IPV has 
an excellent track record on efficacy, it had poor induction of intestinal immunity, 
required cold-chain, booster injections and had expensive and potentially dangerous 
manufacturing processes with the wild type virulent virus. As such, large-scale clinical 
trials were evaluated using several live attenuated PV strains (Melnick and Brennan, 
1959).   
1.2.2 Oral polio virus vaccine 
The Oral Polio Vaccine (OPV) is an attenuated vaccine which has reduced 
worldwide poliomyelitis caused by PV infection. The IPV was the only poliovirus 
vaccine available until licensure of the Oral Poliovirus Vaccine (OPV) in 1961-1962 
(Kew et al., 2005). There was a need for an OPV then as it is a live attenuated vaccine 
which has long-lasting immune response and regular boosters are not needed. One time 
oral administration of the OPV was found to provide lifelong protection against 
poliomyelitis. Elimination of poliomyelitis in the developing world was achieved mainly 
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through mass vaccination with the OPV despite its ability to revert to the wild type in 1 
out of 750,000 vacinees (Kowane et al., 1987). 
The OPV was produced by micro-carrier technology and passaging the virus in 
primary monkey kidney cells at sub-physiological temperatures generated spontaneous 
mutations in the viral genome (Van Wezel, 1967). The mutated strains with low 
virulence were selected and used as vaccines. The process was later scaled up by using 
750-L bioreactors and replacing tertiary monkey kidney cells with Vero cells 
(Thomassen et al., 2013). This has led to successful production of oral polio vaccines 
(OPV) which have reduced worldwide poliomyelitis by the mid-1980s.  
As such, the World Health Assembly declared in 1988 that polio should be 
eradicated by the year 2000, aligned with the success of the small pox eradication 
program.  However, the eradication deadline was repeatedly postponed and has not been 
met till today. This was because there were several countries where polio persistently 
remained endemic such as Afghanistan and Pakistan whereby the population remained 
resistant to polio immunization or India where OPV had low efficacies due to 
overcrowding and poor sanitation (Grassly et al., 2006). Therefore, there is a need to 
have a greater understanding of the molecular determinants of neurovirulence in PV to 
develop new and better vaccines based on genetic manipulations to render the virus non-
pathogenic, yet containing similar antigenic structures to the wild type polio virus.   
1.2.3 Molecular Determinants of Neurovirulence 
The molecular determinants of neurovirulence in PV have been determined. The 
poliovirus is an enterovirus from the Picornaviridae family. The PV has a 5’ non-
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translated (NTR) cloverleaf structure and a 3’-poly (A) tail. Domain I is important for 
virus replication and domains II-VI encompass the internal ribosome entry site (IRES) 
that directs translation of mRNA by internal ribosome binding (Figure 1.2). If there are 
mutations in the 5’-NTR, this decreases multiplication efficiency, alters cell tropism and 
attenuates virulence (Kew et al., 2005).  
There are three attenuated strains being used as OPV: Sabin 1 was derived from 
the Mahoney strain, Sabin 2 was derived from the P172 strain and Sabin 3 was derived 
from the Leon strain. Identification of the genetic determinants of attenuation of the 
Sabin OPV strains has been comprehensively reviewed (Kew et al., 2005). The complete 
sequences of the three poliovirus genomes and the development of infectious poliovirus 
complementary Deoxyribonucleic Acid (cDNA) clones have led to the systematic 
investigations of the critical mutations responsible for the attenuated phenotypes of the 
Sabin OPV strains.  
From the analysis of nucleotide (nt) sequences present in the three poliovirus 
Sabin strains, nucleotide substitutions which were critical in attenuating mutations in the 
virulent strains isolated from cerebrospinal fluid were identified. There are 57 nucleotide 
substitutions distinguishing the Sabin 1 strain from its parent strain (Nomoto et al., 
1982). Among these nucleotide substitutions, the A480G in the IRES is the most 
important determinant of the attenuated phenotype of Sabin 1 (Fig. 1.3). Their study 
strongly suggested that nt. 480 influences the formation of a highly ordered structure in 
the 5’-NTR that is responsible for neurovirulence (Kawamura et al., 1989). Four other 
nucleotide substitutions contributing to the attenuated phenotype were mapped to the 
capsid region. There was one in VP4, one in VP3 and two in VP1. 
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Figure 1.2: Structure and genome of Poliovirus. All structural proteins: VP1-VP4 are encoded by the P1 region of the 
genome. The P2 and P3 genes encode for seven non-structural proteins: 2A-2C and 3A-3D (Kew, et al., 2005).  
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Figure 1.3: Three genotypes of Poliovirus Sabin vaccine strains. All contain a 
determinant of attenuation in the 5’-NTR of ssRNA mutation that reduces viral 
replication. They are nt. 480 in Sabin 1, nt. 481 in Sabin 2 and nt. 472 in Sabin 3 
(Kawamura et al., 1989). 
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In addition, there was also one substitution that contributed to the temperature-sensitive 
phenotype mapped to the 3DPol region (Bouchard & Lam, 1995; Paul et al., 2000).  
However, there were only 2 nt. substitutions found in the Sabin 2 strain that 
appeared at position 481 within the IRES region and position 2909 within VP1 (Figure 
1.3). For Sabin 3, a total of 10 nt. substitutions were found to differ from its parent 
strain, but only 3 substitutions appeared to be the main determinants for the attenuated 
phenotype (C274U in IRES, C2034U in VP3, and U2493C in VP1) (Westrop et al., 
1989). Sabin 3 strain was also found to be the most genetically unstable of the three 
Sabin strains. As a result of the analysis of the molecular determinants of attenuation, in 
vitro construction of piconaviruses with reduced-virulence could be performed via the 
introduction of mutations in the 5’-NTR to reduce the efficiency of viral replication. 
1.3                   Enterovirus 71 as an etiological agent of hand, foot, mouth disease 
1.3.1 Enterovirus 71 
 The World Health Organization (WHO) and the scientific community have been 
addressing challenges unprecedented in public health posed by Enteroviruses in the post-
poliovirus era. Enteroviruses such as Enterovirus 71 (EV-A71), Coxsackie type A16 
(CV-A16) and other enteroviruses causing hand, foot and mouth disease (HFMD) have 
led to over 7 million infections, including 2457 fatalities in China from 2008 to 2012 
(Xing et al., 2014). However, due to increasing travels and rapid globalization, 
outbreaks in other parts of the world have also appeared in other regions in cyclical 
epidemics (Bible et al., 2007).  
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Within the family Picornaviridae, the genus Enterovirus comprises 12 species. 
The species Enterovirus A consists of 25 serotypes and includes the enteroviruses that 
can cause the HFMD are the EV-A71, CV-A16, CV-A5, CV-A6, CV-A8 and CV-A10 
(Pallansch and Roos, 2001). Serotypes such as CV-A4 and CV-A5 are more often 
associated with herpangina. Five years of virological surveillance in China (2008-2014) 
showed that 43.73%, 22.04%, and 34.22% of HFMD cases were due to EV-A71, CV-
A16 and other enteroviruses, respectively (Liu et al., 2015). However, Coxsackie viruses 
which are common etiological agents of HMFD do not generally cause neurological or 
cardiopulmonary disease but EV-A71 is the main causative of fatal HFMD infections 
(Ooi et al., 2010). Of particular interest in this study is EV-A71 as approximately 80-
85% of pathogens isolated from HFMD-related deaths were EV-A71 based on clinical 
etiological data (Ho et al., 1999). Table 1.1 summarizes the various clinical symptoms 
associated with enteroviral infections. 
The EV-A71 virus is classified as Human enterovirus A (HEV-A) species, 
belonging to the genus Enterovirus in the family Picornaviridae, together with some 
Coxsackie A viruses (Brown, 1995). Surveillance data indicated that EV-A71 and CV-
A16 can co-circulate during HFMD outbreaks and such co-circulation may have 
contributed to the genomic recombination between EV-A71 and CV-A16 (Yan et al., 
2012, Yip et al., 2013) which was believed to have led to the emergence of a 
recombinant EV-A71 responsible for the large HFMD outbreak in China in 2008 (Zhang 
et al., 2010). Phylogenetic analysis suggests that EV-A71 originated from CV-A16 from 
as early as 1940 (Tee et al., 2010). EV-A71 isolates of sub-genotypes B3 and C4 had 
high sequence homology to CV-A16 at P2 (≥ 81%) and P3 genomic regions (≥ 83%) 
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(Yoke-Fun and Abu Bakar, 2006). Hence, this corroborates surveillance data of possible 
inter-typic recombination involving EV-A71 and CV-A16. These recombination events 
could have played important roles in the emergence of the various EV-A71 sub-
genotypes.  
The EV-A71 virus is a non-enveloped icosahedral viral particle that contains a 
single-stranded, positive sense, polyadenylated viral Ribonucleic Acid (RNA) of 
approximately 7.4kb (Figure 1.4). The capsid is made up of 60 protomers, each 
consisting of 4 polypeptides that comprise the structural proteins, VP1, VP2, VP3 and 
VP4. Of all the polypeptides, VP4 is located on the internal side of the capsid while 
VP1, VP2 and VP3 are located on the external surface of the EV-A71 virus (SIB Swiss 
Institute of Bioinformatics, 2014).  
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Table 1.1 Clinical manifestations of enteroviruses.  
Each symptom may potentially be caused by more than one enterovirus (Melnick, 1997). 
Enterovirus Serotypes Clinical 
Manifestations 
Poliovirus 1-3, Echovirus 4, 6, 9, 11, 30; Enterovirus 71 
 
Paralysis 
 
Poliovirus 1-3; CV A2, A4, A7, A9, A10, B1-B6;  
Echovirus 1-11, 13 to 23, 25, 27, 28, 30, 31; Enterovirus 71 
 
Aseptic Meningitis  
 
Coxsackievirus A5, A8, A10, A16, Enterovirus 71 Hand, foot and 
mouth disease 
(HFMD) 
 
Coxsackievirus A2 to A6, A8, A10 Herpangina  
 
Coxsackievirus A24, Enterovirus 70 Acute hemorrhagic 
conjunctivitis  
 
Echovirus 2, 6, 9, 19 Encephalitis 
 
Coxsackievirus B1-B5, Enterovirus 71 Meningoencephalitis  
 
Coxsackievirus B3 Pericarditis, 
myocarditis  
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Figure 1.4: Structure and genome of Enterovirus 71. The capsid consists of 60 
protomers, each consisting of 4 polypeptides that comprise the structural proteins: VP1, 
VP2, VP3, and VP4 are encoded by the P1 region of the genome. The P2 and P3 genes 
encode for seven non-structural proteins: 2A-2C and 3A-3D. Reproduced from 
ViralZone, with permission from Philippe Le Mercier, Swiss Institute of Bioinformatics 
(SIB Swiss Institute of Bioinformatics, 2014) 
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The EV-A71 genome comprises a 5’ non-translated region (5’-NTR), a long 
open reading frame (ORF) and a short 3’-NTR followed by a polyadenylated (poly A) 
tail. The 5’-NTR contains an internal ribosome entry site (IRES) which allows viral 
protein translation in a cap-independent manner (Belsham and Sonenberg, 1996). The 
ORF is translated into a single large polyprotein of approximately 2100 amino acids (aa) 
which is divided into three regions (P1-P3). The polyprotein undergoes a series of 
processing events, culminating in the maturation cleavage of the polyprotein which 
generates structural and non-structural viral proteins (Toyoda et al., 1986). The four 
structural proteins, VP1, VP2, VP3 and VP4, are encoded by the P1 region which 
constitutes the virus capsid. Proteins derived from the non-structural P2 (2Apro, 2B, 2BC, 
2CATPase) and P3 (3A, 3AB, 3B, 3Cpro, 3CDpro, 3Dpol) regions are most directly involved 
in virus replication, structural and biochemical changes which are observed within the 
infected cell. (Shen et al., 2008). Non-structural proteins (2A and 3C proteinases) are 
responsible for apoptosis of infected cells in vitro (Kuo et al., 2002; Li et al., 2002). 
The EV-A71 virus commonly causes the hand, foot and mouth disease (HFMD) 
in young children less than 6 years of age. Although EV-A71 started circulating as early 
as 1963 in the Netherlands, EV-A71 was first reported to be isolated in 1969 from the 
stool specimen of an infant with serious nervous system disease in California (Schmidt 
et al., 1974). Mild symptoms of EV-A71 infection in children range from fever (≥ 
39oC), sore throat, loss of appetite and rash with vesicles on hands, foot and mouth area. 
In addition, rupture of the vesicles would lead to ulcers in the throat, mouth and tongue 
(Figure 1.5).  
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Figure 1.5: Vesicles on the foot, mouth and palm area of children infected 
with hand, foot and mouth disease (HFMD). Adapted from the Dermatologic 
Image Database, Department of Dermatology, University of Iowa College of 
Medicine, USA, 1996 (Permission granted by University of Iowa). 
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EV-A71 can produce more severe symptoms such as aseptic meningitis, brain 
stem encephalitis, acute flaccid paralysis, neurogenic pulmonary edema, delayed 
neurodevelopment and reduced cognitive function (Ooi et al., 2010). In 1997, an 
outbreak of EV-A71 caused 41 deaths in Sarawak, Malaysia. This was followed by a 
large outbreak in Taiwan involving over 100,000 cases which led to 78 fatalities (Lin et 
al., 2002). In more recent years, large outbreaks with high fatalities occurred across the 
Asia Pacific in countries like Cambodia, Vietnam and China (Zhang, et al., 2009; Thoa, 
et al., 2013). For example, 54 out of the 78 HFMD cases in a 2012 outbreak in 
Cambodia were highly fatal.  
Xing et al. (2014) discovered that between 2008 to 2012, there were 7, 200, 092 
probable cases of HFMD reported. Approximately 82,486 patients developed 
cardiopulmonary or neurological complications and 1,617 of laboratory confirmed 
deaths were associated with EV-A71. In Vietnam, there were 13 deaths out of 49,317 
cases of infection (WHO, 2014). Some of these young children died of complications 
due to pulmonary edema, while others could not survive brain and spinal cord 
inflammations due to virulent genotypes of EV-A71 (Zhang et al., 2010). The lack of 
vaccines and antiviral drugs against EV-A71 highlights the urgency and significance of 
developing preventive and treatment agents against EV-A71 to prevent further fatalities.  
1.3.2 Distribution of EV-A71 genotypes and sub-genotypes worldwide 
EV-A71 was found to evolve quickly in the past 15 years and many countries experience 
cyclical epidemics (McMinn, 2002). To investigate the genetic variability of various 
EV-A71 strains and their associations with outbreaks, the complete cDNA sequence 
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(891bp) encoding the VP1 capsid protein of EV-A71 strains isolated from various 
countries over a 30-year period was analysed and the monophylogenetic serotype was 
further divided into three distinct genotypes (A, B, C) and 11 sub-genotypes (A, B1-B5, 
C1-C5) (Brown et al., 1999). This was reported by Brown and his colleagues (1999) in 
the phylogenetic analysis of EV-A71 strains (Figure 1.6). In addition, a separate sub-
genotype B0 was proposed after analysing EV-A71 strains from the Netherlands from 
1963 to 1967 (van der Sanden et al.,  2009). A new sub-genotype B6 was isolated in 
Columbia (AF135899), and another new sub-genotype B7 strain was isolated in Brazil 
(AY278249) (Castro et al., 2005).  
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Fig. 1.6: Phylogenetic tree of the VP1 region of EV-A71 strains detected in various 
countries, showing different genotypes and sub-genotypes of EV-A71. Eight hundred 
and fifty-five nucleotide positions in each VP1 region were included in the analysis. The 
tree was constructed by the neighbour joining method and bootstrap values calculated 
from 1,000 trees. The scale bar indicates the estimated number of substitutions per 100 
nucleotides. EV-A71 strains of potential novel genotype or sub-genotype were 
highlighted in gray. GenBank accession numbers are indicated in parentheses (Brown et 
al., 1999; Yip et al., 2013) 
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Genotype A contains a single member, the prototype EV-A71 strain BrCr while 
genotype B has been expanded to include eight sub-genotypes (B0-B7) consisting of 
thousands of strains isolated from 1972 to 2011 in the in the United States, Australia, 
Bulgaria, Columbia, Hungary, Japan, Malaysia, Netherlands, Singapore, Taiwan and the 
UK. Genotype C is made up of five sub-genotypes (C1-C5) which includes EV-A71 
strains isolated from 1986 through to 2010 from Japan, United States, Australia, China, 
Canada, Netherlands, France, Hong Kong, Singapore, Taiwan, Thailand, UK, Germany 
and Malaysia. Two strains belonging to potential new sub-genotype C6 were isolated in 
Taiwan (HM622391 and HM622392) (Figure 1.6). A strain belonging to a new genotype 
D was isolated in India (AY179600) (Yip et al., 2013). Within the same sub-genotype, 
EV-A71 strains share more than 92% nucleotide sequence identity whereas the 
nucleotide sequence identity between the three genotypes ranges from 78% to 83% 
(Brown et al., 1999). The EV-A71 strains had 46% amino acid identity with the 
polioviral P1 capsid region and 55% with the entire polyprotein (Brown and Pallansch, 
1995). 
Lee and co-workers (2012) have established that the B and C genotypes were the 
common ones circulating throughout the world from 1997 to 2012 (Table 1.2). For 
example, EV-A71 outbreaks in Malaysia were caused by different predominant 
genotypes occurring in 1998-2000 (C1 and B4), 2002–2003 (C1, B4 and B5) and 2005-
2006 (C1 and B5). In contrast, EV-A71 infections reported from Singapore have been 
caused mainly by the B sub-genotypes: B3 (1997-1999), B4 (2000-2003) and B5 (2006-
2008) (Table 1.2) (Chan et al., 2003).  
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Table 1.2: Distribution of EV-A71 genotypes throughout the world from 1997 to 2012. 
 
 
1997 1998 
 
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 ‘10 ‘11 ‘12 
 
Malaysia C1,C2,
B3,B4 
C1 C1, B4 B4,C1  C1, B4 B5,B4, 
C1 
B4, 
B5 
B5,C1 B5       
Singapore B3,B4 B3,C1 B3 B4, B5 B4 B4,C1    B5  B5, 
C2 
    
Taiwan  B3,C2, 
C4 
B4 B4 B4, C4 B4,C4 B4 C4 C4 C5 B5,C
5 
B5, 
C4, 
C5 
B5 C4 C4, 
B5 
B5 
Japan C2,C4,
B3,B4 
C2 C2 C2,B4 C2 B4,C2,C4 C4,C1,
B5,B4 
C4  C4 C4      
China C2 C4 B3,C1,
C4 
C1,C4 B4,C4 C1,C2,C4 C2,C4 C4 C2,C4 C2,C4 C2,C
4 
A,B5,
C2, 
C4 
C2, 
C4 
C2,
C4 
C4 C4 
Vietnam         C1,C4,
C5 
       
Australia  C2 B3,C2 B4,C1 B4,C1 C1 C1 C4         
Korea    C3   C4      C2, 
C4 
   
Holland C1,C2  C2 C2 C1 C1, C2  C1, 
C2 
C1, C2  C1, 
C2 
C2 C2    
United 
Kingdom 
C2 C1, C2 C2 C1 C1 C1  C1 C1 C1,C2  C2 C2    
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However, there are some countries such as China whereby the sub-genotype C4 
has been the predominant strain causing fatalities since 1998 based on phylogenetic 
analysis. Hence, biopharmaceutical organisations in China have focused on developing 
the inactivated vaccine to target the sub-genotype C4. In addition to China, the United 
Kingdom (UK) has also experienced infections due to a consistent sub-genotype C1 that 
was responsible for periodic outbreaks since 1998. It remains to be investigated if 
pharmaceutical companies in the UK will be designing vaccines against sub-genotype 
C1. 
1.3.3 Development of Experimental EV-A71 Vaccines 
There is currently no vaccine against EV-A71 that has been approved by the 
United States Food and Drug Administration (FDA) or European Medicines Agency 
(EMEA). Formalin-inactivated EV-A71 vaccines are currently being developed against 
the C4 sub-genotype in China (Li et al., 2014). Although some research groups have 
proposed that the sub-genotype C4 should be classified as genotype D (Chan et al., 
2010), there is increasing evidence that C4 should instead be further subdivided into C4a 
and C4b (Xu, et al., 2013). Each genotype has approximately 15% genetic divergence 
from each other, while each sub-genotype differs genetically from each other by 
approximately 8% (Brown, et al., 1999).  
Immunization with one sub-genotype could potentially cross-protect against all 
other sub-genotypes. This was confirmed from a study by Chou et al. (2012) who 
demonstrated that their inactivated EV-A71 vaccine based on the sub-genotype B4 could 
elicit cross-neutralizing antibody responses against sub-genotypes B1, B5 and C4A. 
36 
 
However, the levels of neutralising antibody titers may not be high enough to be 
protective against all the sub-genotypes. In addition, their vaccine was tested on a small 
sample size of 60 adults. Further research could be carried out to target a larger sample 
size consisting of young children and infants (Chou et al., 2012).  
Huang et al. (2013) conducted studies with children to measure cross-reactive 
neutralizing antibody titres against different EV-A71 genotypes. The serology data 
showed that children infected with genotypes B and C had consistently lower 
neutralizing antibody titres against genotype A (Huang et al., 2013). It could be possible 
that immunization with a particular genotype could elicit higher cross-neutralizing 
antibodies against that particular genotype. For example, a vaccine against genotype C 
could cross-protect against sub-genotypes C1-C5. Zhang et al. (2014) analysed the 
cross-reactive neutralizing antibodies (NtAb) in sera from EV-A71–infected and 
children vaccinated with the inactivated vaccine. They showed that the NtAb titers in 
children elicited by the EV-A71-C4a vaccine were higher against EV-A71-B4, B5, C1, 
C2 and C4b than against other EV-A71 sub-genotypes. Surprisingly, the NtAb titre 
against C4a was always lower than against all other genotypes and this indicated that the 
current genotyping of EV-A71 may not reflect their antigenicity (Zhang et al., 2014). 
1.3.4 Potential candidates for EV-A71 Vaccine 
There is considerable interest in the development of EV-A71 vaccines as HFMD 
has become a severe global and life-threatening disease in infants and young children. In 
2014, China reported over 2.7 million cases of HFMD caused by EV-A71, CVA-16, and 
other enteroviruses, that led to approximately 243 deaths (Western Pacific WHO, 2014). 
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Research groups have developed experimental inactivated vaccines (Liang et al., 2013), 
recombinant VP1 vaccine (Wu et al.,  2001), live attenuated vaccines (Arita et al., 2005, 
Arita et al., 2007), virus-like particles (Li et al., 2013), synthetic peptide vaccine (Foo et 
al., 2007, Kirk et al., 2012) and DNA vaccine (Tung et al., 2007). 
Each type of vaccine has its own advantages and disadvantages. The inactivated 
EV-A71 vaccine is considered the safest viral vaccine as there will be no reversion to the 
infectious wild type strain. Reversion of the live attenuated poliovirus vaccine strains 
generally happens in 1 out of 750, 000 vacinees, but this occurrence will not happen 
with the inactivated poliovirus vaccine. Zhu and coworkers (2014) showed that the 
inactivated EV-A71 vaccine was highly immunogenic and elicited antibodies in children 
with a neutralizing titer of 1:16 and provided protection against mild to severe HFMD 
for at least 1 year in children (Zhu et al., 2014). 
Nevertheless, the inactivated vaccine has several major disadvantages as 
immunogenicity is not long-lasting and requires multiple boosters. This is because 
inactivated vaccines only initiate the humoral immunity and lacks cellular immunity 
(CD8+ T cells) responses. In an inactivated vaccine, there is no viral replication and 
hence, lower antigen content and less prolonged antigen persistence (Zhu et al., 2013). 
As a result, inactivated vaccines elicit weaker and shorter antibody responses and no 
long-term immune memory. This explains the need for multiple boosters after 
administration of inactivated vaccines. Another disadvantage of the EV-A71 inactivated 
vaccine would be their failure to prevent CV-A16 infections and that could compromise 
the acceptability of inactivated monovalent EV-A71 vaccines. The study of Chong et al. 
(2015) also concurred with the results that even though the efficacy of inactivated EV-
38 
 
A71 vaccine was more than 90% against EV-A71-related HFMD, only >80% protection 
against EV-71 associated serious diseases was reported (Chong et al., 2015). 
Increasingly, there has been more research to develop recombinant VP1 vaccines 
that contain VP1 as the major neutralizing antigen, harnessed into vaccine vectors. They 
are advantageous as they are cost-effective immunogens when compared to the 
inactivated vaccines and are safe. This was confirmed by Chen et al. (2006) who showed 
that when transgenic tomatoes expressing the VP1 protein were fed to Balb/c mice as an 
oral vaccine, the serum from the immunized mice showed IgG and IgA neutralizing 
titers of 1:16. The vaccine had elicited both humoral and cellular immune responses 
from the mice. The serum was also able to neutralize EV-A71 infection in 
Rhabdomyosarcoma cells. This demonstrates the potential of recombinant VP1 vaccines 
as good vaccine candidates (Chen et al., 2006).  
However, recombinant VP1 vaccines produced lower levels of NtAb in vacinees. 
This increases the risk of unwanted immune responses such as antibody-dependent 
enhancement (ADE) (Han et al., 2011). ADE is a phenomenon whereby pre-existing 
sub-neutralizing antibodies could not inhibit virus entry and replication. ADE has been 
observed for EV-A71 (Han et al., 2011), poliovirus (Palmer et al., 2000), and CVB 
(Girn et al., 2002). Han and colleagues (2011) demonstrated that previous exposure to 
an avirulent strain of EV-A71 before another EV-A71 infection increased the risk factor 
for developing severe neurological complications and deaths. They also concluded that 
the presence of sub-neutralizing levels of antibodies exacerbated EV-A71 infection (Han 
et al., 2011). The possible impact of ADE has to be taken into account when designing 
vaccines to prevent unwanted induction of enhancing antibodies. Therefore, a better 
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alternative would be to use live attenuated vaccines that elicit the cellular immune 
response, besides the humoral immunity. 
The live attenuated vaccine (LAV) is cheaper to produce, induces excellent 
immunogenicity and confers live-long immunity. LAV is preferred over the inactivated 
EV-A71 vaccine as it can elicit both humoral and cellular immunity, alongside the 
innate and adaptive immunity. There is an increasing body of research which indicates 
that cellular immunity and not humoral immunity determines the clinical outcome of 
EV-A71 infections. In the most severe cases with pulmonary edema, blood samples 
showed lower levels of cellular cytokines and interferons (TNF-α, Th1 and IL-6), while 
there was no difference in the level of NtAb titers between mild, severe and fatal cases. 
Chang and co-workers (2006) also discovered that humoral immunity did not 
affect the clinical outcome in severe cases of EV-A71 infection. This is possible because 
a lower cellular immunity would delay viral killing, increase viral dissemination and 
sustain a systemic inflammatory response that leads to disease severity. This also 
explains why fatal HFMD infections generally afflict infants as they would have weaker 
cellular immunity although they may have maternal EV-A71 NtAb. However, the low 
NtAb levels would have no effect in neutralizing the high EV-A71 viral load (Chang et 
al., 2006). 
In addition, recent research demonstrated that the VP2 antigen subjugates the 
IFN-ᵞ-secreting CD4+ T cell responses against EV-A71, compared with VP1, VP3 and 
VP4 (Tan et al., 2013). This was in contrast to previous investigations on T cell 
immunity that focused on the VP1 antigen as it is highly exposed on the structure of the 
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EV-A71 virus (Figure 1.4). For example, a previous study showed that VP1-145G/Q 
was associated with milder disease, while VP1-145E was associated with disease 
severity (Nishimura et al., 2013). Further research showed that VP1-145G/Q regulated 
the binding of VP1-244K to sulfated Tyr residues at the P-selectin glycoprotein ligand-1 
(PSGL-1) N-terminus on leukocytes (Lee et al., 2013). As PSGL-1 is involved in 
leukocyte migration and cytokine production, EV-A71 interaction with PSGL-1 is vital 
for dissemination within the host and regulation of antiviral host response. These 
discoveries have led to an increased understanding about disease progression of EV-A71 
post-infection, which range from an absence of symptoms (~71%) to fatality (~0.05%) 
(Chang et al., 2002). Taken altogether, an effective LAV should carry both B and T cell 
epitopes. 
However, the disadvantage of LAVs is the possibility of genetic instability and 
possible reversion to wild-type virulence. This phenomenon of reversion has been 
observed in countries with extensive polio LAV programs (Kew et al., 2005). The 
mutation rate of single-stranded RNA viruses is especially high when compared to DNA 
viruses. RNA viruses have a mutability rate of 10-3 to 10-5 mutations per nucleotide 
copied, per replication cycle (Holland et al., 1982). This could be due to the lower 
fidelity of the wild-type RNA-dependent RNA polymerases. They are estimated to 
misincorporate one or two bases in every genome copying event, which explains the 
high mutation rate of RNA viruses (Hicks and Duffy, 2011).  
In addition, as LAVs are excreted from vaccine recipients, they pose a risk to 
immunocompromised individuals who have yet to be vaccinated. The excreted virus can 
mutate to more virulent forms. As a result, regulatory bodies are duly concerned about 
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the safety of such vaccines as there is always a potential of viral escape or mutation to 
revertants. Nevertheless, recent studies have shown that it is possible to generate LAVs 
that have much lower risks of reversion. Meng and Kwang (2014) showed that 
attenuated high-fidelity variants of EV-A71 with a single amino acid change, L123F in 
its 3D Polymerase (3DPol) greatly reduced viral pathogenicity in vivo. These EV-A71 
mutants have lower pathogenicity as they are unable to generate replication-efficient 
mutations and have much lower genetic diversity to withstand a wide range of selective 
pressures (Meng and Kwang, 2014). Hence, high-fidelity EV-A71 variants can reduce 
mutation risk and increase stability of LAVs. With that, there is great potential in LAVs 
and the past success of LAVs for diseases such as poliovirus, yellow fever, rubella, 
measles, mumps, rabies, rotavirus, influenza and varicella zoster has proven that safe 
and effective LAVs can be developed through optimization of immunogenicity and 
genetic stability.    
Since the same Type 1 IRES structure is present in both poliovirus and the EV-
A71 Genotype A (BrCr) genome, Arita and co-workers (2005) introduced 3 mutations at 
nucleotides 485, 486 and 474 in the EV-A71 genome which corresponded to the 
mutations present in Sabin 1, 2 and 3 strains, respectively. They constructed a LAV from 
the BrCr strain (S1-3’) carrying the 3 mutations in the 5’-NTR, 2 mutations in the 3Dpol 
and a single mutation in the 3’-NTR. Although there was reduced virulence, mild 
neurological symptoms were still observed in the 3 cynomolgus monkeys immunized 
with the EV-A71 (S1-3’) strain and the virus was still isolated from the spinal cord. 
Hence, the plan to use this strain as a LAV was discontinued (Arita et al., 2005). The 
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LAV constructed was still able to multiply extensively in the neuronal cells and hence, 
still caused tremors in the monkeys.  
The molecular basis of virulence in EV-A71 is still uncertain. It remains to be 
investigated if there is a universal molecular determinant present in every EV-A71 fatal 
sub-genotype strain or whether every fatal sub-genotype strain differs in virulence 
determinant. In a comparison of the amino acid sequence of the fatal (EV-A71 strain 
5865/Sin/000009) and the non-fatal (EV-A71 strain 5666/Sin/002209) strain isolated 
from the HFMD outbreak in Singapore, Singh and co-workers (2002) reported that a 
nucleotide change at position 5262 in the 3A non-structural region could possibly 
contribute to the virulence of EV-A71 strain 41. Comparative analysis revealed 99% 
amino acid similarity except for the amino acid 1506. The fatal strain contains adenine at 
position 5262 that encoded for threonine, while the non-fatal strain contains guanine that 
encoded for alanine (Singh et al., 2002) (Figure 1.7).  
Li et al. (2011) compared the sequences of virulent and non-virulent strains and 
concluded that four amino acids at two positions (Gly/Gln/Arg in position 710 and Glu 
in position 729) in the VP1, one (Lys in position 930) and four nucleotides at three 
positions (G in position 272, U in position 488 and A/U in position 700) in the 5’-NTR 
region are likely to contribute to the EV-A71 virulent phenotype (Li et al., 2011). In 
another study, Yeh et al. (2011) reported that nucleotide 158 in the EV-A71 5’-NTR 
contributed to the virulence of the virus belonging to the sub-genotype B1 (Figure 1.8).  
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Figure 1.7: Differences of nucleotide between the B4 genotype fatal strain 
(GenBank: AF316321) and the non-fatal strain 10 (GenBank: AF352027). There is 
99% nucleotide similarity, except at nucleotide 5262 in the 3A non-structural region 
(Singh et al., 2002). 
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Figure 1.8: A single nucleotide change from Cytosine to Uridine at position 158 in 
Stem Loop II of 5’-NTR contributes to virulence of EV-A71 sub-genotype B1 in 
mice. This nucleotide change led to reduced viral translation and virulence in mice (Yeh 
et al., 2011). 
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A single nucleotide change from cytosine to uridine at position 158 caused an 
alteration in the RNA secondary structure of stem loop II which led to reduced viral 
translation and virulence in mice (Yeh et al., 2011). An earlier study published by Izuka 
et al. (1989) demonstrated that deletion from nucleotides 564 to 726 in the 5’-NTR of 
the poliovirus Mahoney genome was successfully expressed as a stable, less 
neurovirulent phenotype. Mutant strains carrying long deletions maybe more stable and 
safer than those carrying point mutations, short deletions or short insertions. 
With the discovery of virulence determinants for some EV-A71 sub-genotypes, 
rational design of a LAV based on site-directed mutagenesis of specific nucleotides 
allows control of the primary structure of proteins. Therefore, it is of interest that by 
changing the nucleotides in the virulence-associated positions of the viral genome, 
neurovirulence can be reduced and genetic stability increased to reduce the possibility of 
reversion to virulence. However, complete stability may be difficult to attain as there 
may be other virulent determinants of attenuation that have yet to be discovered. In 
addition, recombination between different group C enteroviruses occur so frequently in 
humans that exchange of the attenuation region maybe inevitable, especially if there is 
high circulation of viruses (Liu et al., 2014).  
Recent research has also focused on virus-like particles (VLP) as good vaccine 
candidates. VLPs resemble the authentic virus in terms of morphology, capsid proteins 
and protein composition, but are devoid of genetic material. Hence, VLPs are not 
infectious but can self-assemble in eukaryotic expression systems such as 
Saccharomyces cerevisiae (Li et al., 2013) and Pichia pastoris (Cereghino and Cregg, 
2000). More importantly, VLPs contain an arrangement of epitopes on its surface that 
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can elicit NtAb against that particular virus. Indeed, VLPs have been developed as 
licensed vaccines for human papillomavirus (Paavonen, et al., 2007) and Hepatitis B 
virus (Roldao et al., 2010). Therefore, there remains potential for VLPs to be an 
excellent choice of vaccine for EV-A71. In a recent publication by Zhang et al. (2015), 
high yield production of recombinant VLPs of EV-A71 (approximately 150 mgVLP/liter 
of yeast culture) was achieved in Pichia pastoris. Maternal immunization with the VLP 
co-expressing P1 and 3CD proteins of EV-A71 was able to protect neonatal mice in both 
intraperitoneal and oral challenge against EV-A71. The transgenic Pichia pastoris 
produced more VLPs than that reported for baculovirus/insect cell expression system as 
the latter only produced 64.3 mg/L under optimized condition (Paavonen, et al., 2007). 
The overall cost of insect cell culture is relatively high and there is a potential risk of 
contamination with baculovirus particles. Recombinant virus-like particles produced 
from baculovirus formulated with CFA/IFA adjuvants elicited a neutralization titer of 
1/160 which was significantly lower than the neutralization titer (1/640) elicited by the 
inactivated EV-A71 formulated in alum (Chou, et al., 2012). 
In addition, there is an increasing trend to develop a bivalent VLP vaccine 
against both EV-A71 and CAV 16 as both viruses tend to co-circulate in major HFMD 
outbreaks. There has been a greater understanding of the crystal structure of the EV-A71 
virus. Lyu et al., (2014) discovered that at least 18 residues from the N-terminus of VP1 
BC loop are transiently externalized, making it suitable for foreign peptide insertion for 
the generation of recombinant EV-A71 viruses. It was observed that such insertions did 
not affect the capsid structural changes and virus uncoating process. This would provide 
more insights into vaccine development against HFMD. In their more recent study, they 
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deduced that the crystal structures of EV-A71 VLP and chimeric EV-A71/CV-A16 VLP 
contained major neutralization epitopes of EV-A71 that are mostly preserved in both 
VLPs. The replacement of 4 amino acid residues in the VP1 GH loop of the SP70 
epitope was able to change the chimeric VLP to elicit neutralization responses against 
both EV-A71 and CV-A16.  The mutated VP1 GH loop in the chimeric VLP was well 
exposed on the particle surface and exhibited a surface charge potential different from 
that contributed by the original VP1 GH loop in EV-A71 VLP (Lyu et al., 2015).  
Xu and co-workers (2014) demonstrated that passive transfer of neutralizing 
monoclonal antibody (nMAb) against the VP2 protein of EV-A71 protected BALB/c 
mice against lethal EV-A71 infection. Interestingly, they showed that the cross-
neutralizing EV-A71 antibodies were induced using hepatitis B virus core protein (HBc) 
as a carrier, and the VP2 epitope (amino acids 141-155) was able to elicit neutralizing 
antibodies with a titer of 1/32 and conferred 100% in vivo passive protection (Xu et al., 
2014). Taken altogether, a broad-spectrum vaccine strategy targeting the high-affinity 
epitopes of VP1 and VP2 may elicit effective immune responses against EV-A71 
infection.  
In exploring peptide vaccines, there are many benefits such as no risk of 
reversion, increased stability and induction of specific NtAbs. Synthetic peptide 
vaccines against HFMD contain EV-A71 neutralization B-cell epitope such as the SP70 
from the VP1 protein of EV-A71 strain 41. This SP70 peptide was able to elicit NtAb 
against different EV-A71 sub-genotypes. When anti-SP70 sera was passively 
administered into suckling Balb/c mice, followed by lethal challenge with various EV-
A71 genotypes (B2, B5, C3, C4), neutralizing antibodies elicited by SP70 were able to 
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confer good passive protection (Foo et al., 2007). However, protection of mice was 
found to be only at 80%. When compared to the inactivated and recombinant VP1 
vaccines, immunogenicity of peptide vaccines is low (Chou et al., 2012). Low levels of 
NtAb may also lead to unwanted side effects like ADE.  
The immunogenicity of peptide vaccines can be further increased when they are 
co-delivered with strong mucosal-immune adjuvants or nanoparticles (Gregory et al., 
2013). However, the usage of strong adjuvants such as complete Freund's adjuvant is not 
acceptable for human use and even incomplete Freud's adjuvant is reactogenic and may 
be responsible for cold abscesses. Currently, aluminium salts and MF59 are the only 
vaccine adjuvants approved for human use. The low immunogenicity of peptide 
vaccines could be due to structural and conformational differences between the peptide 
that is synthesized in a recombinant protein expression system which differs from the 
endogenous EV-A71 viral protein. More studies could be performed to identify 
Enterovirus-specific and cross-genotype neutralization epitopes in VP1 that could 
induce a protective immune response to ensure high levels of NtAb responses.  
Recent investigations showed that peptide vaccines based on recombinant 
multiple tandem linear neutralizing epitopes (mTLNE) have been constructed by linking 
VP1-SP55, VP1-SP70 and VP2-SP28 with a Gly-Ser linker. It was demonstrated that 
passive transfer of anti-mTLNE sera was able to confer full protection in neo-natal mice 
against lethal EV-A71 challenge by inducing both the humoral and cellular immunity 
(Li et al., 2014). In addition, a recent study was performed by Xu and co-workers (2014) 
who also constructed a recombinant vaccine containing the epitope within the VP2 EF 
loop. They discovered that passive transfer of anti-sera that was induced by the 
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recombinant VP2 vaccine were able to protect newborn mice against EV-A71 lethal 
challenge with a cross-neutralizing titer of 1:32 (Xu et al., 2014) 
DNA vaccines comprise of DNA coding for a particular antigen which can be 
directly injected into the human muscle. The DNA antigen gene encoded by the DNA 
vector would then manufacture that particular antigen in the host cells. The host immune 
system would recognize the antigen as a foreign substance and hence, produce NtAbs 
against it. DNA vaccines have many advantages as they are very stable and easy to 
manufacture. However, no DNA vaccines have been found to elicit substantial immune 
response that is needed to prevent an infection, which was a major disadvantage. 
Nevertheless, Tung and co-workers (2007) managed to construct a DNA vaccine that 
was able to elicit NtAb response in Balb/c mice. The anti-VP1 IgG in the mice that had 
been immunized with the DNA vaccine exhibited neutralizing activity against EV-A71 
(Tung et al., 2007). In another study, a DNA vaccine was able to induce cellular and 
humoral immune responses which were capable of providing protection against 
Chikungunya virus challenge in mice (Mallilankaraman et al., 2011). To date, no DNA 
vaccines have been commercialized (Nakayama and Aruga, 2015). 
1.3.5 Inactivated EV-A71 Vaccines 
Up to date, five organizations have completed pre-clinical studies to develop an 
inactivated vaccine which is at different phases of clinical trials. Three of the companies 
are from mainland China while the other two are from Taiwan and Singapore. The three 
China-based biopharmaceutical companies are Vigoo, Sinovac and Chinese Academy of 
Medical Science (CAMS). They have all completed Phase III Clinical Trials in 2014 for 
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an inactivated EV-A71 vaccine against the sub-genotype C4 as it was the main sub-
genotype responsible for outbreaks in China (Table 1.3). The three companies conducted 
randomized, double-blind, placebo-controlled, multicentre trials involving 10,007-
12,000 healthy children. Each vaccine candidate received two intramuscular doses of 
vaccine or placebo within a span of 28 days apart (Liang and Wang, 2014). 
Sinovac reported that their inactivated vaccine efficacy was 94.8% and anti-EV-
A71 immune response elicited by the two dose vaccines were found in 98.8% of 
participants. In addition, the anti-EV-A71 neutralizing titre of 1:16 associated with 
protection against EV-A71 was intended to last for at least 1 year. However, the NtAb 
titre declined 50% after 6 months (Li et al., 2014). In addition, there were different NtAb 
levels induced by the 3 vaccine strains although they were all from the sub-genotype 
C4a strain. 
The NtAb levels (VNA GMT) in children vaccinated with the inactivated 
vaccines produced by Sinovac and CAMS were 191 and 170 at 1 year post-vaccination 
and 4 weeks, respectively. The lowest VNA GMT was observed with the inactivated 
EV-A71 vaccine from Vigoo at a VNA GMT of 92 at 1 year post-vaccination. This 
could be due to the different manufacturing processes, cell substrates, culture systems 
and vaccine doses used by the 3 companies (Chong et al., 2015). Mao et al. (2012) also 
discovered that the aluminium hydroxide adjuvant used, though similar in concentration, 
had differing immunological-enhancing effects. Compared with the vaccine strains 
without the adjuvant, the differences in immunogenicity among the vaccine strains 
absorbed with alum adjuvant produced by the three manufacturers were reduced, 
especially at 14-day and 28-day after immunization.  
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Table 1.3: Five EV-A71 inactivated vaccines at different clinical phases of development. 
 
Organizations 
Cell lines&EV-A71 
strain 
Clinical trials 
Dosage (µg of 
EV-A71 
antigen) 
Population target Current status of 
clinical trial 
      Adjuvant Technology for vaccine 
production 
NHRI (Taiwan) 
Vero cell  & EV-
A71 
B4 (GMP-certified) 
5 and 10 Young adults 
Phase 1 completed 
 
 
Aluminium phosphate 
 
 
Roller bottles 
Sinovac (China) 
 
Vero cell & EV-
A71 
C4  
1 
 
Young adults, 
young children 
and infants 
Phase III completed 1, 
2 and 3 completed 
 
 
Aluminium hydroxide 
 
 
Cell factory 
Beijing Vigoo 
(China) 
Vero cell & EV-
A71 
C4  
0.8 
 
Young adults, 
young children 
and infants 
Phase III completed 
Phase 1, 2 and 3 
completed 
 
 
Aluminium hydroxide 
 
 
Microcarrier bioreactors, 
fermentation cylinder 
CAMS (China) 
Human diploid cell 
KMB-17 & EV-A71 
C4  
 
0.25 
 
 
Young adults, 
young children 
and infants 
Phase III completed 1, 
2 and 3 completed 
 
Aluminium 
hydroxide, glycine 
 
 
Microcarrier bioreactors 
Inviragen 
(Singapore) 
Vero cell & 
EV-A71 B3  
0.3 and 3 Young adults 
Phase 1 completed 
Phase 1 
Completed 
Aluminium hydroxide Cell factory 
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The inactivated vaccines containing aluminium adjuvants when used at the lowest dose 
(162U) showed good protective effects in sucking mice against lethal challenge (90-
100% survival).   
The inactivated vaccines should also be based on international manufacturing 
process criteria, global vaccine standards and high regulation of quality. Currently, roller 
bottles and cell factories are employed for upstream cell culture but they are labour 
intensive. Chong et al. (2012) reported the feasibility of producing a C4-based protective 
vaccine (0.25 µg) at US$0.1/dose using a 40-L pilot scale batch reactor. Upstream 
manufacturing processes could be further improved with the use of bioreactors, micro-
carriers and perfusion technology. To lower the production cost, a simple and efficient 
downstream chromatographic purification step will need to be incorporated (Chong et 
al., 2012). To determine the potency and efficacy of inactivated vaccines produced by 
different manufacturing processes, there is a need for standardization of the vaccine 
strain, quality control reagents, immunoassays and animal models at the international 
level. A global surveillance network for enterovirus outbreaks is needed to monitor 
immune responses to the inactivated EV-A71 vaccine.   
Prior to the release of the inactivated EV-A71 vaccine, there were a few studies 
that are addressing whether the NtAb elicited by one EV-A71 sub-genotype could cross-
neutralize other sub-genotypes or confer protection across genotypes or sub-genotypes. 
For example, it was reported that neutralizing antibodies elicited by 10 strains of the C4 
genotype in rabbits had variable cross-neutralizing effects against different strains of the 
same sub-genotype and the genotype A BrCr strain (Mao et al., 2012), while another 
study demonstrated that mice challenged with lethal doses of B3 genotype survived due 
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to prior vaccination with a C4 genotype vaccine (Bek et al., 2011).  In addition, Zhang et 
al. (2014) showed that the titers of NtAb in children elicited by the EV-A71-C4a vaccine 
were higher against EV-A71-B4, B5, C1, C2 and C4b than against other EV-A71 sub-
genotypes. Interestingly, the NtAb titers raised against the C4a sub-genotype used for 
immunization was lower than those of all the other EV-A71 sub-genotypes and this 
indicated that the current genotyping scheme may not truly reflect their antigenicity 
(Zhang et al., 2014).  
It is important to conduct studies with more antisera collected from future phase 
III clinical trials to further evaluate the efficacy of cross-protection against all EV-A71 
genotypes and sub-genotypes, determine the types of immune response and understand 
immune correlates of protection. There is no data to show vaccine efficacy against 
serious EV-A71-associated neurologic disease, such data might become available after 
the vaccines are licensed and post marketing surveillance is undertaken. A global 
surveillance network to monitor the emergence of new EV-A71 after the introduction of 
the vaccine should be established. As the child needs to be immunized with the 
commercial pentavalent vaccine, the EV-A71 vaccine could be included in the 
Expanded Programme on Immunization Vaccines. 
There also remains insufficient information on the inactivated EV-A71 vaccine-
induced immunity to ensure wide and safe use of the vaccine inside and outside of 
China. Samples collected during Phase III Clinical Trials should be analyzed for 
immune response types and immune correlates of protection (Lu, 2014). Also, as 
Coxsackie type A16 (CV-A16) is also a leading cause of severe HFMD infections, there 
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should be more research into formulating a combined EV-A71-CA16 vaccine to 
effectively prevent severe HFMD outbreaks. 
1.3.5 Immunogenicity of vaccines 
Vaccines against viral diseases could be potentially improved if the 
immunogenicity of the vaccine could be enhanced. A major hurdle to the development 
of LAVs is the difficulty in achieving a satisfactory level of attenuation without severely 
compromising rate of replication and immunogenicity. Many factors such as safety have 
to be taken into consideration during the development of live viruses as potential LAVs.  
Bukreyev et al. (2002) have discovered that immunogenicity in primates of a 
LAV for human parainfluenza virus type 3 (HPIV3) could be enhanced by expression of 
granulocyte–macrophage colony-stimulating factor (GM-CSF) from an extra gene 
inserted into the genome of a cDNA-derived virus. GM-CSF is a major cytokine vital in 
the maturation and activation of dendritic cells and macrophages. Their recombinant 
GM-CSF HPIV3 virus showed a decrease in viral replication by 40-fold when compared 
to the wild type HPIV3. In addition, this attenuated vaccine virus expressing GM-CSF 
displayed 3- to 6-fold higher NtAb levels than that induced by the non-attenuated wild 
type virus (Bukreyev et al., 2002). As the NtAb titer is vital to confer life-long 
protection against any virus, their LAV maybe a suitable candidate against the HPIV3 as 
it has high immunogenicity and low pathogenicity. 
Another major factor that should be taken into consideration when developing a 
LAV strain would be the monitoring of antigenic variations of EV-A71. A study 
conducted by Chia et al (2014) showed that rabbits immunized with genotype B and C 
viruses consistently had lower NtAb titers against genotype A (≥ 8-fold difference) and 
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antigenic variations between genotype B and C viruses could be detected but did not 
have a clear pattern. This was consistent with previous human studies (Huang et al., 
2010). A rabbit model was used as it was difficult to obtain large amounts of sera from 
children for neutralization assays.  
Interestingly, the authors deduced that sub-genotype B2 and B5 viruses were 
highly immunogenic and could induce high NtAb titers against all genogroup B and C 
viruses (Chia et al., 2014). This was consistent with serology data from Huang et al. 
(2013) that showed children infected with genotypes B and C consistently have lower 
NtAb titers against genotype A (4-fold difference). Sequence comparisons revealed that 
five amino acid signatures (N143D in VP2; K18R, H116Y, D167E, and S275A in VP1) 
were responsible for the antigenic variations in genotype A. This further corroborates the 
idea that vaccine development should monitor the antigenic and genetic variations of 
each EV-A71 genotype/sub-genotype. 
1.4 Aims of Study 
Arita et al. (2005) had attempted to develop a live-attenuated vaccine (LAV) 
against EV-A71 by introducing 3 mutations at nucleotides 485, 486 and 475 in the EV-
A71 genotype A genome which corresponded to the mutations present in Sabin 1, 2 and 
3, respectively. Although there was reduced virulence, mild neurological symptoms 
were still observed in the 3 cynomolgus monkeys that received intravenous inoculation 
with the EV-A71 (S1-3’) strain carrying mutations in the 5’NTR, 3Dpol and in the 
3’NTR. However, the virus still caused tremors and was isolated from the spinal cord. 
Hence, this strain did not meet the criteria to be used as a LAV.  
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The inactivated EV-A71 vaccine has been advanced to almost production level in 
the next 12 months in China. However, the lack of long-term protection has necessitated 
the search for other types of vaccines. LAVs have been the focus of current research and 
development. This type of vaccine induces excellent immunogenicity, elicits humoral 
and cellular immunity and thereby, confers live-long immunity. It can be introduced via 
oral delivery like the OPV. 
In this study, we are investigating if EV-A71 sub-genotype B4, strain 41 
(5865/Sin/000009) has a different virulence determinant from the sub-genotype B1 
(clinical isolate 237) reported by Yeh et al. (2011). The EV-A71 sub-genotype B4 virus 
(accession number: AF316321) will be modified to carry a single mutation at nucleotide 
position 158 by site-directed mutagenesis to assess if the nucleotide is a common 
virulence determinant between sub-genotypes B4 and B1 (Fig. 1.9). An EV-A71 mutant 
bearing a long deletion in the 5’-NTR of the genome will also be constructed. The 
virulence of the various mutated EV-A71 strains will be evaluated in the 
Rhabdomyosarcoma (RD) cell culture by plaque assays, viral infectivity by tissue 
culture infectious dose (TCID50) determinations, real time Reverse-Transcriptase 
Polymerase Chain Reaction (RT-PCR) and detection of VP1 by immunoblotting with 
monoclonal antibody directed at VP1. RD cells are chosen as they were very efficient in 
exhibiting cytopathic effect typically 7-10 days after inoculation (Pallansch and Ross, 
2001).  
Our first objective in this study is to genetically modify the EV-A71 strain 41 
(sub-genotype B4) virus by substituting nucleotides at positions 158, 475, 486, and 487 
based on the fact that these nucleotides are responsible for the neuro-virulence of 
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poliovirus Sabin strains 1, 2 and 3 (Table 1.4). The virulence determinants of poliovirus 
and EV-A71 reported in previous studies served as references in this study to produce 
EV-A71 viruses that are highly attenuated. Figure 1.9 illustrates the predicted RNA 
secondary structure of EV-A71 strain 41 from nt. 474 to 541. 
 
Table 1.4: Common genetic determinants between EV-A71 and Sabin polio strains. 
Nucleotide Substitution Position in Sabin strains Position in EV-A71 strain 
41 
C to T 472 475 
A to G 480 486 
G to A 481 487 
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Figure 1.9: Predicted RNA secondary structure of EV-A71 strain 41 from nt. 474 to 
541. Due to slight differences in the length of the 5’-NTR, nt. 480 in Sabin 1 is at the 
equivalent position 486 (1) in this figure. Nt. 481 in Sabin 2 is at the equivalent position 
487 (2), and nt. 472 in Sabin 3 is at the equivalent position 475 (3) of the EV-A71 
genome (Yin Quan Tang, personal communication, 2014). 
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Our second aim for this study is to investigate if the single nt. difference (strain 
41) between the fatal and the non-fatal strain (strain 10) is responsible for neuro-
virulence by introducing a nt. substitution at nt. position 5262 in the EV-A71 viral 
genome. This is to be carried out with reference to a previous study conducted by Singh 
et al. (2002). The nt. at position 5262 will be changed from A to G.  
Our third objective is to construct a genetically stable and safe LAV through 
partial deletion of the 5’-NTR region in the EV-A71 genome. This may reduce the 
efficiency of viral replication as Izuka et al. (1989) was able to generate genetically 
stable poliovirus. Deletion will be created from nt. positions 475 to 485. Our final 
objective is to evaluate the virulence of the various EV-A71 mutants in vitro in RD cells 
and the in vivo immunogenicity of the various mutants.
CHAPTER 2 
MATERIALS AND METHODS 
 
2.1 Cell Culture  
Human Rhabdomyosarcoma cells (RD, ATCC # CCL-136) were cultured in 
Dulbecco's modified Eagle's minimal medium/F-12 (DMEM/F-12, Invitrogen, USA), 
supplemented with 10% foetal bovine serum (FBS) (Gibco, USA), 1% 
penicillin/streptomycin, 1% L-glutamine and 1% essential amino acids. All cell lines 
were grown at 37°C in 5% CO2 until 80-90% confluency. 
2.2 Viral infection 
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RD cell monolayers in 75-cm2 flasks were inoculated with 100µL EV-A71 strain 
5865/Sin/000009 (GenBank accession number AF316321). Infected cells were 
incubated with 1 mL DMEM containing antibiotics but no serum at 37°C until the 
complete cytopathic effect (CPE) was apparent. RD cells were frozen at −80°C and 
thawed, three times, and cell debris was removed by centrifugation at 14,000 x g for 10 
minutes at 4°C. Supernatants were used for harvesting the virus. 
2.3 RNA Extraction and Reverse Transcription 
Viral RNA was extracted from EV-A71 using the QIAmp® Viral RNA Mini Spin 
Kit (Qiagen, Calif., USA). The kit was used according to the manufacturer’s 
instructions. The purified RNA was reverse transcribed into cDNA by using the 
SuperScript® III First Strand Synthesis SuperMix Kit (Invitrogen, Calif., USA). Each 
cDNA synthesis mixture contained 10X annealing buffer, 25mM MgCl2, 0.1 M 
oligo(dT), RNAseOUT/Superscript III RT and viral RNA as template. 
2.4 Cloning of EV-A71 cDNA into the pCR-XL-TOPO vector 
Full length cDNA of EV-A71 was amplified using polymerase chain reaction 
(PCR). Each PCR reaction contained 5X Phusion HF buffer, 10mM dNTP, 0.1g of each 
primer, 1 µg template cDNA and Phusion HSII DNA Polymerase. The following cycling 
conditions were employed for the PCR reactions: 98oC for 30s, followed by 98oC for 
10s, 64oC for 30s and 72oC for 5 min for 30 cycles. The cycles were terminated with a 
30s extension at 68oC. The amplified cDNA was cloned into the pCR®-XL-TOPO® 
vector (Invitrogen, Calif., USA). 
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Approximately 100 ng of the full length EV-A71 cDNA was ligated to 1µL 
pCR®-XL-TOPO® vector according to the manufacturer’s protocol in the TOPO® XL 
PCR Cloning Kit (Invitrogen, Calif., USA) (Figure 2.1). The ligation mixture was 
incubated for 5 min at room temperature, then 1 µl of the 6x TOPO® Cloning stop 
solution was added and the tubes were placed on ice. The recombinant EV-A71 pCR-
XL-TOPO vector (Fig.2.1) was stored at -20oC for further downstream processes. 
2.5 Site-directed mutagenesis 
The EV-A71 full genome in the pCR-XL-TOPO plasmid acted as the substrate for single 
mutations using designed primers (Table 2.1) and the QuickChange Lightning Site-
Directed Mutagenesis Kit (Agilent Technologies, Calif., USA). EV-A71 mutants were 
constructed by introducing site-directed mutations at nucleotide positions 158, 475, 486, 
487, in the 5’-NTR and at position 5262 of the viral genome, respectively. In the 1st 
stage of the reaction, PCR was carried out. The mixture contained 10x reaction buffer, 
100ng/µl of each primer, 100ng ds DNA template, 1µL dNTP mix and 1µL QuikChange 
Lightning Enzyme mix. The PCR mixture was added up to a total reaction volume of 50 
µl. The PCR conditions were set up at 95°C for 2 min for initial denaturation, followed 
by 18 cycles of 95°C for 20 sec, 60°C for 10 sec, 68°C for 5 min 30 sec. Final 
elongation was carried out at 68°C for 5 min. 
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Figure 2.1: Schematic illustration of EV-A71 cDNA clone in pCR-XL-TOPO.  
EV-A71 genomic cDNA was cloned downstream of a SP6 RNA polymerase promoter. 
The in vitro transcribed positive-sense RNA carried an additional G residue at the 5’ end 
and a poly(A)50 tail followed by additional CGGCC residues at the 3’ end. The arrow 
indicates the transcription start site. 
 
Table 2.1: Primers used for site-directed mutagenesis and partial-deletion in the 5’-
NTR of EV-A71 genome. 
 
Name Sequence (5’-3’) 
EV-5UTR-F(A486G) GCTAATCCTAACTGTGGGGCACATGCCTTCAATCC 
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EV-5UTR-R(A486G) GGATTGAAGGCATGTGCCCCACAGTTAGGATTAGC 
EV-5UTR-F(G487A) GCTAATCCTAACTGTGGAACACATGCCTTCAATCCAG  
EV-5UTR-R(G487A) CTGGATTGAAGGCATGTGTTCCACAGTTAGGATTAGC 
EV-5UTR-F(C475T) CCCTGAATGCGGCTAATTCTAACTGTGGAGCACA 
EV-5UTR-R(C475T) TGTGCTCCACAGTTAGAATTAGCCGCATTCAGGG 
EV-5UTR-F(A5262G) GTCGTGCAATCCATCGCTACTGTGGTGGCAG 
EV-5UTR-R(A5262G) CTGCCACCACAGTAGCGATGGATTGCACGAC 
EV-5UTR-F(A158T) GGCGCACCAGCTTTGTCTTGATCAAG 
EV-5UTR-R(A158T) CTTGATCAAGACAAAGCTGGTGCGCC 
EV-UTR-F(∆11) AGCACATGCCTTCAATCCAGAGGG 
EV-UTR-R(∆11) ATTAGCCGCATTCAGGGGCCGGAG 
 
 
 
 
 
In the 2nd stage of mutagenesis, 2 µl of the Dpn I restriction enzyme was added 
to the amplification product to digest the methylated and hemimethylated parental DNA. 
The ligation mixture was incubated for 5 min at 37°C. In the 3rd stage, transformation 
was performed using XL 10-Gold® Ultracompetent cells (Agilent Technologies, Calif., 
USA). The ligated mixture (2 µl) was added to the competent cells and incubated on ice 
for 30 min. The cells were then subjected to heat shock at 42°C for 30 sec, and 
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immediately placed on ice for 2 min. An aliquot of the NZY+ broth (500 µl) was added 
to the XL 10-Gold competent cell suspension, followed by shaking of the transformed 
bacterial cells at 37°C for 1 hour.  
After the 1 hour incubation, tubes were centrifuged at 13,000 x g for 1 min. Clear 
supernatant was discarded and the cell pellet was resuspended in 500 µl of fresh NZY+ 
medium and an aliquot of 0.2 ml was plated on LB agar supplemented with 25 µg/ml 
kanamycin sulphate (Invitrogen, Calif., USA). The E.coli cells were incubated overnight 
for 16h at 37°C. Figure 2.2 shows a schematic representation of the site-directed 
mutagenesis (SDM) steps. Nucleotide substitutions were confirmed by DNA sequence 
analysis using nucleotide Basic Local Alignment Software (BLAST by NCIB). 
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Figure 2.2: Schematic representation of the Site-Directed Mutagenesis (SDM) steps. 
The diagram was adapted with modifications from the instruction manual for the 
QuikChange® II XL Site-Directed Mutagenesis Kit (Stratagene). 
x – Indicates positions of the mutated nucleotides both within the mutagenic primers and 
newly synthesised DNA. 
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2.6 Storage of transformed E. coli cells containing recombinant plasmid with 
the desired mutations 
For short term storage, E. coli cells carrying the recombinant plasmid on plates 
were stored at 4oC for up to one month. For longer term storage, transformed bacteria 
were maintained in LB broth supplemented with 20% glycerol (v/v) and stored at -80oC. 
To revive the E. coli from the glycerol stock, a sterile wire loop was placed into the 
glycerol stock and cells that were picked up were streaked onto a LB agar plate 
containing 25 µg/ml kanamycin. The plate was incubated for 16h overnight at 37oC. 
2.7 Partial-deletion in the 5’-NTR of EV-A71 genome 
EV-A71 with a partial deletion from nucleotide positions 475 to 485 in the 5’-
NTR was constructed using two designed primers that were 24 nucleotides in length 
[namely EV-UTR-F(∆11) and EV-UTR-R(∆11)] (Table 2.1) and the Q5® Site-Directed 
Mutagenesis Kit (New England Biolabs, USA) (Chua et al., 2008). The melting 
temperature of the primers were approximately 63oC, determined using the calculation 
below: 
Tm = 81.5 + (0.41)(%GC) - 675/N - % mismatch,  
where N = primer length in bases, (%GC) and % mismatch = whole numbers 
The EV-A71 deletion mutant was confirmed by DNA sequence analysis by 
nucleotide Basic Local Alignment Software (BLAST by NCIB). Bacterial colonies that 
carried the viral genome with the correct mutations were kept in 20% glycerol stock at -
80oC for long term storage. 
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2.8 Plasmid isolation and purification 
The recombinant EV-A71 pCR®-XL-TOPO® plasmid was isolated from 5 ml of 
overnight culture of E. coli with Endofree Plasmid Purification Kit (QIAGEN, Calif., 
USA) following the manufacturer's recommended protocol. Extracted plasmid was 
eluted in 300 µl of TE Buffer and stored at -20°C. 
2.9 Restriction endonuclease digestion of plasmid DNA  
Plasmid DNA (30 µg) purified from the E.coli transformants was digested with 
EagI (New England BioLabs, Massachusetts, USA). The reaction was incubated at 37oC 
in a water bath for 2h. Screening of DNA fragments after digestion of the recombinant 
pCR-XL-TOPO EV-A71 plasmid was carried out using DNA agarose gel 
electrophoresis. The agarose gel was pre-stained with GelRed nucleic acid stain 
(Biotium, USA) prepared in 0.5X TAE buffer. DNA products were mixed with gel 
loading buffer and loaded into wells in the agarose gel. Electrophoresis was carried out 
using 80V and DNA bands were illuminated with UV light. The size of the DNA 
fragments were compared with a GeneRuler 1 kbp DNA ladder (Invitrogen, USA).  
2.10 Phenol-chloroform purification and ethanol precipitation of DNA 
 
 The DNA solution was mixed with an equal volume of phenol-chloroform 
(Amresco, Calif., USA) and vortexed for 1 min. The mixture was centrifuged at 15,000 
x g for 10 min to separate the aqueous and solvent phases. The desired aqueous layer 
was carefully removed and mixed with an equal volume of phenol-chloroform (1:1) 
(Amresco, Calif., USA) and vortexed for 1 min. The mixture was again centrifuged at 
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15,000 x g for 10 min. The aqueous layer was removed and 1/10 volume of chilled 3M 
sodium acetate (pH 5.2) and 1/10 volume of isopropanol were added to the DNA sample 
and mixed well by inverting the tube multiple times.  
Then, the sample was incubated at -20oC for 2h to precipitate the DNA. The 
DNA was pelleted by centrifugation at 15,000 x g for 30 minutes at 4oC. The 
supernatant was carefully removed and 1 ml of cold 70% ethanol was added to wash off 
the remaining salts. The DNA pellet was allowed to air dry for 5 minutes with the lid 
opened. The desired amount of TE buffer was added into the tube in order to dissolve 
the DNA.  
2.11 Production of infectious EV-A71 RNA from cloned cDNA 
RNA transcription was carried out using RiboMAX™ Large Scale RNA 
Production System-SP6 (Promega, Calif., USA). The reaction was set up in 20 µl of 
reaction volume by following the recommended protocol. The reaction mixture was 
subjected to incubation at 37°C for 4h and followed by DNase treatment for 30 minutes. 
The DNase (Promega, Calif., USA) was added to the in vitro transcription reaction at a 
final concentration of 1 U per µg of DNA template. The Linear Control DNA supplied 
by RiboMAX™ Large Scale RNA Production System-SP6 was used as a template for 
production of RNA transcripts of approximately 1.8 kb in length and served as a positive 
control for the in vitro transcription reaction. The in vitro transcribed EV-A71 RNA was 
visualized by agarose gel electrophoresis prior to being used in transfection of RD cells 
(Han et al., 2010). 
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2.12 Transfection of RD cells with in vitro RNA transcripts 
RD cells were seeded in a 24-well plate and incubated for 24 h. When the cell 
confluence reached about 50%, transfection was performed following the manufacturer's 
instructions with the use of Lipofectamine 2000 reagent (Invitrogen, Calif., USA) with a 
multiplicity of infection (MOI) of 0.1. Unbound viruses were washed away 4h after 
infection and cells were then cultured in fresh medium containing 10% fetal bovine 
serum. Once cytophatic effects (CPE) were observed (round and shrunken cells), the 
mutated viruses were harvested. 
2.13 Plaque Assay 
A 6-well plate with 6 X 105 RD cells/well was prepared and incubated overnight 
at 37oC in 5% CO2. Prior to viral infection, the complete growth medium (DMEM 
supplemented with 10% FBS) was removed and approximately 1 mL serial 10-fold 
dilutions of virus inoculum was added to the cells for 1 h at room temperature with 
gentle shaking to allow for virus attachment. After 1 h incubation, the inocula was 
removed and replaced with 2 mL of 1.2% w/v carboxylmethylcellulose. After 72 h 
incubation, the plaque medium was removed and the cells were fixed with 4% 
formaldehyde and stained with 0.5% crystal violet. The plaques were visible against a 
white background. The plaque forming unit per millilitre (PFU/ml) was calculated using 
the formula: 
PFU/ml = Number of plaques X Dilution factor 
        Volume of inoculum (mL) 
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2.14 Tissue Culture Infectious Dose (TCID50) Assay 
The EV-A71 mutant virus titers were quantitatively determined by TCID50. 
TCID50 refers to the quantity of a virus that will produce a cytopathic effect in 50% of 
the cultures inoculated. The TCID50 assay was carried out in RD cells using the Reed 
and Muench formula (Appendix VII). A monolayer of RD cells from a 75cm2 tissue 
culture flask was harvested after trypsinization with 3 ml of trypsin-EDTA (Gibco, 
Calif., USA) and the addition of MEM growth media to obtain a final concentration of 1 
x 103 cells /μl.  
To assay the number of infectious virions in a purified virus stock, serial 10-fold 
dilutions of the stock virus suspension in quadruplicates, were carried out in a 96-well 
microtiter plate using MEM growth media as diluent. The negative control wells 
contained RD cells without any virus. The plate was incubated at 37oC and observed 
daily for CPE up to 48h. 
 
2.15 Real-Time RT-PCR 
Total RNA was extracted from various EV-A71 mutant strains grown in RD 
cells the inocula using the RNeasy extraction kit (Qiagen, USA). Quantitative real-time 
PCR was performed using the Applied Biosystems 7500 Sequence Detection system 
(Applied Biosystems, USA), with 4 μl of RNA template, 10 μl of 2x SensiFAST probe 
No-ROX One Step Mix, 0.8uL Forward and Reverse primer (10uM), 0.2 µL probe 
(10uM), 0.2 µl reverse transcriptase, and 0.4 µL RiboSafe RNase inhibitor (BioLine, 
California, USA) contained in 20 μl of the final reaction mixture. The reaction was 
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performed for one cycle at 48oC for 10 min, 95°C for 2 min, followed by 40 cycles at 
95°C for 5s and 60°C for 20s in a 96-well plate. Three independent experiments were 
conducted for each sample. Threshold cycle value (Cq) data was determined using 
default threshold settings, and the mean Cq was calculated from the duplicate PCRs. A 
standard graph was plotted based on a series of standard solutions. 
2.16 EV-A71 VPl Immunoblot 
Total cellular proteins were extracted by incubating wild-type and EV-A71 
mutant cells in lysis buffer (20 mM Tris-HCl, pH 7.4, 1% Nonidet P-40, 137 mM NaCl, 
50 mM EDTA, protease inhibitor mixture and 1 mM phenylmethylsulfonyl fluoride). 
After centrifugation at 14,000 x g for 10 min at 4°C, supernatants were transferred and 
mixed with an equal amount of protein sample buffer (120 mM Tris-HCl, pH 8.0, 20% 
glycerol, 4% SDS, 2.5% β-mercaptoethanol and 0.05% bromophenol blue). Lysates 
were separated by SDS-PAGE and transferred to nitrocellulose membrane (Millipore, 
Calif., USA) that had been blocked with 5% BSA in Tris-Buffered Saline and Tween 20 
(TBST) buffer for 1 h at room temperature. The membrane was then incubated overnight 
at 4°C with anti-enterovirus VP1 monoclonal antibody (LifeSpan BioSciences, Calif., 
USA) diluted in the blocking buffer. After hybridization with primary antibody, the 
membrane was washed three times with TBST before hybridizing with anti-mouse HRP 
secondary antibody (Sigma Aldrich, St Louis, USA) diluted in TBST. The blots were 
then washed three times with TBST and detected by chemiluminescence using 
ImageQuant (GE Healthcare Life Sciences, Calif., USA). 
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2.17 Immunization of mice 
Inbred Balb/c mice were purchased from Monash University. All institutional guidelines 
for animal care and use were strictly followed throughout this study. Heat inactivation of 
EV-A71 virus was carried out for 30 min at 56oC and the PFU determined. Groups of 5 
adult (6 weeks old) female Balb/c mice were intraperitoneally immunized with either 
103 TCID50 of EV-A71 mutant strain or the positive control EV-A71 strain 41 (10
3 
TCID50) in a 50% emulsion of Freund’s complete adjuvant (Sigma Aldrich, Calif., 
USA). Two booster doses in 50% emulsion with Freund’s incomplete adjuvant (Sigma 
Aldrich, Calif., USA) were administered to the mice at 3 weeks intervals. The volume of 
each vaccine suspension administered was 400 μl. The blood from the mice were 
collected 7 days after the last immunization. To collect the immune sera, blood was 
centrifuged at 6000 x g for 15 min to precipitate the blood cells. Sera containing EV-
A71-neutralizing antibodies were pooled and stored at -80oC until use. 
2.18 EV-A71 neutralization assay.  
The presence of neutralizing antibodies against EV-A71 was determined by an in vitro 
microneutralization assay using RD cells, as described previously (Foo et al., 2007). 
Murine antisera were first incubated at 56°C for 30 min to inactivate the complement 
activity. Briefly, 25 µl of twofold serial dilutions of the heat-treated serum was 
coincubated with an equal volume containing 103 50% tissue culture infective doses of 
virus (TCID50) in a 96-well microtiter plate. Two hours later, 5 X 10
4 RD cells were 
added to each well and incubated at 37°C for 48 h. The cells were examined for CPE 
after 48h and the neutralizing antibody titer was defined as the highest dilution of serum 
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that inhibited virus growth by 100%, thereby preventing CPE. The assay was performed 
three times independently. 
2.19  IgG-subtying 
The profiles of specific IgG subtypes in the mice hyperimmune sera were determined by 
a commercially available mouse sub-type isotyping kit (Thermo Scientific., Rockford, 
USA) according to the manufacturer’s instructions. Pouches of cassettes from the kit 
were removed from refrigeration and equilibrated fully to room temperature. Mouse 
serum was diluted 1:100 by adding 50 µL of serum to 450 µL of sample diluent and 
vortexed to mix. The diluted sample (150µL) was added to the well of each cassette. 
Red colour bands appeared after 5-10 minutes. In brief, the gold conjugates embedded in 
the cassette form specific class- and subclass-soluble complexes with the antibodies in 
the serum sample. These complexes travel the length of the membrane and are resolved 
on the anti-isotype and class-specific antibody-impregnated membrane. Results are 
displayed as a red band indicating the antibody isotype or subclass. 
2.20 Bioinformatics Analysis 
The protein sequence of EV-A71 viral proteins was analysed and alignment of the amino 
acid sequences was undertaken by using the Clustal method of DNASTAR MegAlign. 
Predictions of 5’NTR secondary structures of probable base pairs predictions, which 
might include pseudoknots was conducted by using databases such as RNA Structure at 
Rochester University: http://rna.urmc.rochester.edu/RNAstructureWeb/index.html and 
the mfold Web Server at http://molbiol-tools.ca/RNA_analysis.htm. 
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2.21 Statistical Analysis 
Means ± standard deviations were obtained from at least two independent biological 
replicates. Statistical significance was calculated using the Mann-Whitney test. A P 
value of < 0.05 was considered as statistically significant. 
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CHAPTER 3 
 
RESULTS 
 
3.1 Molecular Basis of Pathogenicity 
 
It remains to be investigated if there is a universal molecular determinant present 
in every EV-A71 fatal sub-genotype strain or whether every fatal sub-genotype strain 
differs in virulence determinant. Yeh et al. (2011) reported that the virulence 
determinant in an EV-A71 sub-genotype B1 (clinical isolate 237) was a single 
nucleotide change from cytosine to uridine at position 158. The EV-A71 sub-genotype 
B4 virus (accession number: AF316321) was genetically modified to carry a single 
mutation at nucleotide position 158 by site-directed mutagenesis to assess if the 
nucleotide is a common virulence determinant between sub-genotypes B4 and B1. The 
effect of this change was evaluated by qualitative assays such as cytopathic effects 
(CPE) in Rhabdomyosarcoma (RD) cells. Mutant EV-A71 158 (A158T) had minimal 
CPE when transfected into RD cells with a MOI of 0.1 (Figure 3.1A) as compared to the 
positive control (EV-A71 wild type strain 41) (Figure 3.1C). CPE was seen as round and 
shrunken cells that floated on the surface and there was extensive CPE seen with the 
EV-A71 wild type strain 41 cells. All experiments were repeated at least three times on 
separate days.   
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             (A) 
 
(B)          (C) 
 
Figure 3.1: Cytopathic effects (CPE) caused by (A) the mutant EV-A71 158 
(A158T) in Rhabdomyosarcoma (RD) cells in comparison with (B) uninfected RD 
cells (negative control using Opti-MEM) and (C) EV-A71 wild type strain 41 
infected RD cells (positive control). Transfection of infectious RNA into RD cells was 
performed with the use of Lipofectamine 2000 reagent using EV-A71 mutants with a 
MOI of 0.1. CPE was seen as round and shrunken cells that eventually dislodged from 
the surface. Magnification used (X 100). 
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The EV-A71 strain 41 virus was also genetically modified by substituting 
nucleotides at positions 475, 486, and 487 as these nucleotides were responsible for the 
neuro-virulence of poliovirus Sabin strains 1, 2 and 3 (Table 1.4). The virulence 
determinants of poliovirus and EV-A71 reported in previous studies served as references 
in this study to produce EV-A71 viruses that might become highly attenuated. The 
mutant EV-A71 475 (C475T) (Figure 3.2A) caused the lowest CPE in RD cells when 
compared to mutants 486 (A486G) (Figure 3.3A) and 487 (G487A) (Figure 3.4A). Out 
of the three mutants, A486G demonstrated the highest amount of CPE (Figure 3.3A) as 
evident from the rounding and shrunken nature of many cells. EV-A71 mutant 487 
(G487A) displayed intermediate CPE when transfected into RD cells with a MOI of 0.1 
(Figure 3.4A). 
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                                                                 (A) 
 
 
(B)          (C) 
 
Figure 3.2: Infection of RD cells by (A) the mutant EV-A71 475 (C475T) in RD cells 
in comparison with (B) uninfected RD cells (negative control using Opti-MEM) and 
(C) EV-A71 wild type strain 41 infected RD cells (positive control). Transfection of 
infectious RNA into RD cells was performed with the use of Lipofectamine 2000 
reagent using EV-A71 mutants with a MOI of 0.1. CPE was seen as round and shrunken 
cells that eventually dislodged from the surface. Magnification used (X 100). 
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(A) 
 
(B)            (C) 
 
Figure 3.3: CPE caused by (A) the mutant EV-A71 486 (A486G) in RD cells in 
comparison with (B) uninfected RD cells (negative control using Opti-MEM) and 
(C) EV-A71 wild type strain 41 infected RD cells (positive control). Transfection of 
infectious RNA into RD cells was performed with the use of Lipofectamine 2000 
reagent using EV-A71 mutants with a MOI of 0.1. CPE was seen as round and shrunken 
cells that eventually dislodged from the surface. Magnification used (X 100). 
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         (A) 
 
 
(B)              (C) 
 
Figure 3.4: CPE caused by (A) the mutant EV-A71 487 (G487A) in RD cells in 
comparison with (B)  uninfected RD cells (negative control using Opti-MEM) and 
(C) EV-A71 wild type strain 41 infected RD cells (positive control). Transfection of 
infectious RNA into RD cells was performed with the use of Lipofectamine 2000 
reagent using EV-A71 mutants with a MOI of 0.1. CPE was seen as round and shrunken 
cells that eventually dislodged from the surface. Magnification used (X 100). 
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Analysis of the genomic sequences of two EV-A71 strains, one isolated from a 
non-fatal case and another isolated from a fatal case shows that the single nucleotide (nt) 
difference between the fatal strain (EV-A71 strain 5865/Sin/000009, designated as strain 
41), and the non-fatal strain (EV-A71 strain 5666/Sin/002209, designated as strain 10) 
might be responsible for neuro-virulence. This is based on the previous study by Singh 
et al. (2002) where they indicated the difference between the fatal and non-fatal strain is 
at nucleotide (nt) position 5262. In the current investigation, the Adenine residue at 
position 5262 present in the fatal strain (strain 41) was changed to the Guanine residue. 
Based on the morphology as shown in Figure 3.5A, RD cells showed no CPE as cells 
were relatively healthy when compared to the extensive lysis observed with the positive 
wild type control (Figure 3.5C). There was hardly any floating cells observed and this is 
similar to no CPE being observed with the negative control (without virus) (Figure 
3.5B). 
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(A) 
 
(B)             (C) 
 
Figure 3.5: Infection of RD cells by (A) the mutant EV-A71 5262 (A5262G) in RD 
cells in comparison with (B) uninfected RD cells (negative control using Opti-
MEM) and (C) EV-A71 wild type strain 41 infected RD cells (positive control). 
Transfection of infectious RNA into RD cells was performed with the use of 
Lipofectamine 2000 reagent using EV-A71 mutant 5262 with a MOI of 0.1. CPE was 
seen as round and shrunken cells that eventually dislodged from the surface (C). 
Magnification used (X 100). 
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An EV-A71 mutant that carried a partial deletion in the 5’-NTR region in the 
viral genome was also constructed. This was carried out to reduce the efficiency of viral 
replication as Iizuka et al. (1989) had created a deletion in this region to generate 
genetically stable poliovirus (Iizuka et al., 1989). In this study, deletion was created 
from nt. positions 475 to 485 (∆11). The mutant EV-A71 PD (Partial Deletant 5’-NTR) 
did not show any CPE (Figure 3.6A) and the microscopic image showed similarity with 
the image taken from the uninfected RD cells that acted as a negative control (Figure 
3.6B). These microscopic images are in direct contrast to the extensive CPE microscopic 
image recorded for the EV-A71 wild type strain 41 (Figure 3.6 C).  
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(A) 
   
(B)           (C) 
 
Figure 3.6: Infection of RD cells by (A) the mutant EV-A71 PD (Partial Deletant 5’-
NTR) in RD cells in comparison with (B) uninfected RD cells (negative control 
using Opti-MEM) and (C) EV-A71 wild type strain 41 infected RD cells (positive 
control). Transfection of infectious RNA into RD cells was performed with the use of 
Lipofectamine 2000 reagent using EV-A71 mutants with a MOI of 0.1. CPE was seen as 
round and shrunken cells that eventually dislodged from the surface (C). Magnification 
used (X 100). 
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3.2 Quantification of Viral RNA Copy Number 
  Observation of CPE in Rhabdomyosarcoma (RD) cells is a qualitative indication 
of the extent of infectivity of the various mutants in comparison with the EV-A71 wild 
type strain 41. Approaches such as determination of the viral RNA copy number, plaque 
forming units (PFU), 50% tissue culture infectious doses (TCID50) and amount of viral 
capsid protein 1 (VP1) present in each strain will enable a better quantitative comparison 
of attenuation of the various mutant strains. The viral RNA copy number of the various 
EV-A71 mutant strains was evaluated after growing in the Rhabdomyosarcoma (RD) 
cell culture for 24 hours.  
RD cells infected with the wild type EV-A71 strain 41 gave the highest yield of 
viral RNA copy number (5.5 X103). As for EV-A71 mutant 475 and PD, low copy 
number was detected for both mutants at 1.02 X 102 and 1.05 X 102 viral RNA, 
respectively. From Figure 3.7, there are a few positions that appear to attenuate the virus 
when the mutated strains were evaluated in vitro. For example, EV-A71 mutant 158 
mutated at position 158 (A158T) gave a yield of 2.0 X 103 RNA copy number which is 
slightly less than that of the wild type RNA copy number. Amongst all the mutants 
being evaluated, mutant 486 carrying SDM at position 486 (A486G) expressed the 
highest viral RNA copy number of 4.2 X103 when compared to the wild type strain 41. 
The mutant 487 carrying SDM at position 487 (G487A) produced a viral RNA copy 
number of 2 X 102. The mutant 5262 with a SDM at position 5262 also showed much 
reduced viral RNA copy number of 7 X 102. Attenuated strains with low viral RNA 
copy number are possible good vaccine strains as they cannot replicate fast enough and 
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yield high viral load to cause destruction of the tissue cells. Slow replication could infer 
that the cells could still carry enough antigens to stimulate an immune response.  
Based on the viral RNA copy number, the mutations introduced at positions 486 
and 158 have contributed to slight attenuation of the infectivity but both of the mutants 
are not suitable to serve as live attenuated vaccine strain (LAV). The mutation 
introduced at position 5262 had considerably reduced the viral RNA copy number to 10-
fold less when compared to the wild type copy number. Therefore, mutant 5262 will 
need to be further evaluated on plaque forming units, TCID50 and the amount of VP1 
formed. Minimal RNA copy number (1.2 X 10²) was expressed by mutants 487, 475 and 
PD. These three mutants appear to hold promise and will be subjected to further 
evaluation tests to assess whether they could serve as potential LAV strains. 
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Figure 3.7: Quantification of Viral RNA Copy Number. 
The viral RNA copy number was quantified at 24h post-infection by TaqMan Real-Time 
PCR. Viral RNA copy numbers are the average of three biological replicates; Error bars 
represent the standard deviation of the mean. 
 
 
 
 
 
 
88 
 
3.3 Quantitation of virus by tissue culture infectious dose (TCID50)  
The tissue culture infectious dose (TCID50) for the EV-A71 wild type strain 41 
and mutant virus titers were quantitatively determined. TCID50 refers to the quantity of 
virus that will produce a cytopathic effect in 50% of the cultures inoculated.  
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Fig. 3.8: Schematic diagram of the TCID50 assay for enumerating EV-A71 viruses. The virus samples were added to column 1 and serially diluted 1:10 across 
the plate to column 9 (added directly to the cells). The negative control – (C) wells contained RD cells without any virus. The wells that have red spots indicate 
cell death while red wells indicate healthy cells. The TCID50 assays were performed on monolayer RD cells incubated at 37oC and were repeated at least two 
separate times.    
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Table 3.1: Tissue Culture Infectious Dose 50 (TCID50) of EV-A71 mutants in 
comparison with EV-A71 strain 41 and the negative control. 
The plate was incubated at 37oC and observed daily for CPE up to 48h. The TCID
50
/ml 
values are calculated using the Reed and Muench formula (Reed, and Muench, 1938) 
determined from at least two independent experiments. The formula is presented in 
Appendix VII. 
 
EV-A71 Mutants TCID50  
A158T 1.00 X 104 
C475T 1.00 X 106 
A486G 1.00 X 104 
G487A 7.50 X 105     
A5262G  3.41 X 105        
Partial Deletant (PD) 5’-NTR 1.00 X 106 
Positive Control (EV-A71 strain 41) 1.00 X 103 
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This study also further investigated whether the different EV-A71 mutants 
exhibited reduced EV-A71 viral growth. As shown in Table 3.1, EV-A71 mutant 158 at 
position 158 demonstrated a higher TCID50 of 1.00 X 10
4 when compared against the 
positive control EV-A71 wild type strain 41 (TCID50 of 1.00 X 10
3). This indicates that 
EV-A71 mutant 158 would require a higher quantity of virus (approximately 10 times) 
to produce a cytopathic effect in 50% of the cultures inoculated (Figure 3.8).  
  In addition, the mutant 486 carrying SDM at position 486 also had 10 times 
increased value of TCID50 value (1.00 X 10
4) when compared with the positive control 
EV-A71wild type strain 41, suggesting that the mutant had decreased virulence. Both 
mutants 5262 with a SDM at position 5262 and mutant 487 showed more than 100-fold 
increase in TCID50 value when compared against the EV-A71 wild type strain 41. 
Mutant 475 with SDM at position 475 and mutant PD both showed a significant 1000 
fold increase in TCID50 to 1.00 X 10
6 (Table 3.1). 
 Analysis of the TCID50 values indicates that mutant 475 and the partial deletant 
(PD) required higher doses of viruses to cause cytopathic effects in 50% of the tissue 
culture. Thus, mutants 475 and PD may serve as potential LAV candidates for further 
evaluations by other tests in vitro. 
 
  
  
 
 
92 
 
3.4 Quantification of virus by the plaque assay 
The number of plaques produced by the various EV-A71 mutant strains was 
evaluated in the Rhabdomyosarcoma (RD) cell culture by plaque assays. Our objective 
is to evaluate the ability of the various mutants to form plaques. Prior to viral infection, 
the complete growth medium was removed and 1 mL of 10-fold dilutions of virus 
inoculum was added to the cells and incubated for 1 h at 37oC. After 1 h incubation, the 
inoculum was removed and replaced with 3 mL of 1.2% w/v CMC. After 72 h 
incubation, the plaque medium was removed and the cells were fixed with 4% 
formaldehyde and stained with 0.5% crystal violet stain. 
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 (a)   EV-A71 (Strain 41) (158)                 (475)                        (486) 
                
(5.0 x 107 PFU/mL)   (20 x 104 PFU/ml)   (7.0 x 104 PFU/mL)    (35 x 104 PFU/ml) 
Viral count: 5.0x107             2.0x105           7.0x104          3.5x105 
(b)  EV-A71 (487)           (5262)            (PD)         Negative Control 
   
(10 x104 PFU/mL) (18 x 104 PFU/mL)    (9.0 x 104 PFU/mL)   (0 PFU/mL) 
Virus titer: 1.0x105  1.8x105       9.0x104            0  
Figure 3.9: Quantification of plaque forming units by EV-A71 mutants and wild 
type EV-A71 strain 41. 
(a) Quantification of plaque forming units by the wild type EV-A71 strain 41, mutants 
158, 475, and 486.  
(b) Quantification of plaque forming units by the EV-A71 mutants 487, 5262, partial 
deletant 5’-NTR (PD) and the negative control (uninfected RD cells). The plaque assays 
were performed on monolayer RD cells incubated at 37oC and were repeated at least two 
separate times.  
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Figure 3.10: Plaque Forming Units by EV-A71 mutants and the wild type EV-A71 
strain 41. 
RD cells were transfected with EV-A71 mutants and the wild type EV-A71 strain 41 at a 
MOI of 0.1. Plaque formation was observed 72 hours post-infection. PFU numbers are 
the average of two biological replicates; Error bars represent the standard deviation of 
the mean. 
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RD cells infected with the wild type EV-A71 strain 41 gave the highest number 
of plaques (5.0 x 107 PFU/mL). The least number of viral plaques were formed by the 
mutant 475 carrying SDM at position 475 (7.0 x 104 PFU/mL) and the partial deletant 
(PD) in the 5’-NTR (9.0 x 104 PFU/mL) (Figure 3.10).  
From analysis of the data presented in Figure 3.10, there are a few positions in 
the viral genome that are likely to attenuate the virus. The EV-A71 mutant 158 (SDM at 
position 158) gave a yield of 2.0 x 105 PFU/ml and the mutant 486 also had reduced 
plaque number (3.5 x 105 PFU/ml) when compared to the positive control (EV-A71wild 
type strain 41), albeit at a much higher copy number than the mutant 487 carrying SDM 
at position 487 (1.0 x105 PFU/mL). The mutant 5262 with a SDM at position 5262 also 
showed much reduced plaque number (1.8 x 105 PFU/mL). As the ability to form 
plaques is reduced for certain mutant strains, viral growth is lower. This would mean 
that viraemia caused by a lower number of viruses will be milder as viral load would 
affect pathogenicity. 
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3.5 Western Blotting 
The ability of the various mutated EV-A71 strains to produce viral particles 
could be evaluated by detection of VP1 by immunoblotting with the monoclonal 
antibody directed at VP1. Supernatant derived from transfected RD cells was processed 
and subjected to electrophoresis to separate the EV-A71 total proteins. The amount of 
VP1 present in each mutant was assessed by the Western blot analysis. A single band 
was revealed at an approximate molecular weight (MW) of 32kDa (Figure 3.10). This 
band corresponds to the VP1 monomer with an apparent MW of 32.7kDa.  
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Figure 3.11: Western blot analysis using monoclonal antibody against VP1 as the 
primary antibody.  
 
The amount of EV-A71 total proteins and β-actin loaded in each lane was 5 μg. The 
lanes are as follows: lane M, molecular weight marker (from 10 - 250 kilodaltons), lane 
1, EV-A71 Mutant 158; lane 2, EV-A71 Mutant 475; lane 3, EV-A71 Mutant 486; lane 
4, EV-A71 Mutant 487; lane 5, EV-A71 Mutant 5262; lane 6, EV-A71 Mutant Partial 
Deletant (PD) 5’-NTR; lane 7, Positive control (EV-A71 Virus); lane 8, Negative 
control (RD cells). The molecular weights of the EV-A71 protein and β-actin are 36 kDa 
and 32.7 kDa, respectively. Arrow indicates the presence of VP1 in respective lanes. 
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RD cells infected with the wild type EV-A71 strain 41 (Lane 7) demonstrated the 
largest amount of VP1 protein (32.7 kDa) detected in Western blot analysis. Minimal 
amount of VP1 was detected in the mutant strain 475 carrying the site specific mutation 
at position 475 (Lane 2) and the partial deletant (PD) in the 5’-NTR (Lane 6). This was 
consistent with results from plaque assays, TCID50, and RT-PCR. From Figure 3.10, 
there are a few nucleotide (nt) positions in the viral genome that are likely to attenuate 
the virus as we can observe the amount of viral capsid VP1 being formed are less than 
the amount of VP1 being formed by the wild type strain 41.  For example, EV-A71 
mutant 158 at position 158 (Lane 1) and mutant 5262 (Lane 5) showed much reduced 
amounts of viral VP1 protein when compared to the wild type EV-A71 (Lane 7). 
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3.6 Determination of neutralizing antibody titer elicited by the EV-A71 wild 
type strain 41 in comparison with the various EV-A71 mutants. 
 
Eight groups of 5 female Balb/c mice were immunized intraperitoneally with 
either the heat-inactivated EV-A71 mutants 158, 475, 486, 487, 5262, PD, and the EV-
A71 strain 41 or PBS which represented positive and negative controls, respectively. 
The neutralizing activities of individual antisera obtained from the same group of mice 
were determined by an in vitro microneutralization assay. The infectivity of the various 
EV-A71 mutants and the EV-A71 wild type strain 41 was observed in RD cells over a 
period of 48 hours. 
The anti-EV-A71 wild type immune serum allowed complete protection from 
cytopathic effect (CPE) of the RD cells at serum dilutions up to 1:32 (Figure 3.12). 
Complete protection of RD cells from CPE was also observed with serum dilutions 
ranging from neat to 1:32 for antisera obtained from mice immunized with the EV-A71 
mutants 5262 (A5262G) (Figure 3.17) and PD (Figure 3.18). In contrast, the neutralizing 
activity of antisera from mice immunized with the EV-A71 mutant 158 (A158T) against 
the EV-A71 wild type strain 41 was significantly lower with a neutralizing antibody titer 
of 1:8 (Figure 3.13). However, the pooled antisera from mutants 475 (C475T) (Figure 
3.14), 486 (A486G) (Figure 3.15), and 487 (G487A)-immunized mice (Figure 3.16), 
displayed similar neutralizing activity with each other and with a neutralizing antibody 
titer 1:16. These data demonstrate that the neutralizing levels of the immune sera 
obtained from the mutants 5262 (A5262G) (Figure 3.17) and PD-immunized mice 
(Figure 3.18) were as good as those elicited by the wild type strain 41. Mice immunized 
with the mutants 475 (C475T), 486 (A486G) and 487 (G487A) contained 2-fold less 
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neutralizing antibodies than the levels observed with those elicited by the wild-type 
strain 41, mutants 5262 and the PD (Table 3.2). 
 
Table 3.2: Neutralizing antibody titers elicited by heat-inactivated EV-A71 mutants 
and EV-A71 strain 41 in mice. 
 
Two-fold serial dilutions of heat-inactivated serum were co-incubated with 103 TCID50 
in a 96-well plate. Two hours later, 5 X 104 RD cells were added to each well and 
incubated at 37°C. The cells were examined for CPE after 48h. 
 
Immunogen Neutralizing Antibody Titer 
Positive Control (EV-A71 strain 41) 1:32 
A158T 1:8 
C475T 1:16 
A486G 1: 16 
G487A 1: 16 
A5262G 1:32 
Partial Deletant(PD)5’-NTR 1:32 
 
 
 
 
 
 
 
 
 
101 
 
(A)   Neat             (B) 1:8 
      
(C)  1:16                                                            (D) 1:32 
  
      (E) 1:64 
 
Figure 3.12: In vitro microneutralization assay using pooled antisera from mice 
(n=5) immunized with the heat-inactivated EV-A71 wild type strain 41. RD cells 
were infected with 103 TCID50 EV-A71 pre-incubated with various dilutions of anti-EV-
A71 immune serum. Survival of RD cells was observed with the neat serum (A); 
antiserum dilution of 1:8 (B); antiserum dilution of 1:16 (C); antiserum dilution of 1:32 
(D); but not with antiserum dilution of 1:64 (E). 
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(A) Neat             (B) 1:8 
                 
      (C) 1:16 
 
 
Figure 3.13: In vitro microneutralization assay using pooled antisera from mice 
(n=5) immunized with the heat-inactivated EV-A71 mutant 158 (A158T). RD cells 
were infected with 103 TCID50 EV-A71 pre-incubated with various dilutions of the anti-
EV-A71 mutant 158 (A158T) immune serum. Survival of RD cells was observed with 
the neat antiserum (A); antiserum dilution of 1:8 (B); but not with antiserum dilution of 
1:16 (C). 
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(A) Neat      (B) 1:8 
          
    (C) 1:16                                                                          (D) 1:32 
 
 
Figure 3.14: In vitro microneutralization assay using pooled antisera from mice 
(n=5) immunized with the heat-inactivated EV-A71 mutant 475 (C475T). RD cells 
were infected with 103 TCID50 EV-A71 pre-incubated with various dilutions of the anti-
EV-A71 mutant 475 (C475T) immune serum. Survival of RD cells was observed with 
the neat antiserum (A); antiserum dilution of 1:8 (B); antiserum dilution of 1:16 (C); but 
not with antiserum dilution of 1:32 (D). 
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(A) Neat      (B) 1:8 
   
(C) 1:16      (D) 1:32 
   
 
Figure 3.15: In vitro microneutralization assay using pooled antisera from mice 
(n=5) immunized with the EV-A71 mutant 486 (A486G). RD cells were infected with 
103 TCID50 EV-A71 pre-incubated with various dilutions of the anti-EV-A71 mutant 
486 (A486G) immune serum. Survival of RD cells was observed with the neat antiserum 
(A); antiserum dilution of 1:8 (B); antiserum dilution of 1:16 (C); but not with antiserum 
dilution of 1:32 (D). 
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(A) Neat      (B) 1:8 
     
(C) 1:16      (D) 1:32 
     
                                          
Figure 3.16: In vitro microneutralization assay using pooled antisera from mice 
(n=5) immunized with the EV-A71 mutant 487 (G487A). RD cells were infected with 
103 TCID50 EV-A71 pre-incubated with various dilutions of the anti-EV-A71 mutant 
487 (G487A) immune serum. Survival of RD cells was observed with the neat antiserum 
(A); antiserum dilution of 1:8 (B); antiserum dilution of 1:16 (C); but not with antiserum 
dilution of 1:32 (D). 
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(A) Neat                       (B) 1:8 
     
(C) 1:16     (D) 1:32 
   
(E) 1:64 
 
Figure 3.17: In vitro microneutralization assay using pooled antisera from mice 
(n=5) immunized with the EV-A71 mutant 5262 (A5262G). Survival of RD cells was 
observed with the neat antiserum (A); antiserum dilution of 1:8 (B); antiserum dilution 
of 1:16 (C); antiserum dilution of 1:32 (D); but not with antiserum dilution of 1:64 (E).  
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(A) Neat    (B) 1:8 
    
(C) 1:16     (D) 1:32 
   
(E) 1:64 
 
Figure 3.18: In vitro microneutralization assay using pooled antisera from mice (n=5) 
immunized with the heat-inactivated EV-A71 mutant PD (deletant in the 5’NTR). Survival 
of RD cells was observed with the neat antiserum (A); antiserum dilution of 1:8 (B) antiserum 
dilution of 1:16 (C); antiserum dilution of 1:32 (D); but not with antiserum dilution of 1:64 (E). 
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3.7 Analysis of IgG responses elicited by EV-A71 Mutants 
One of the goals for vaccination is to induce a strong and long memory humoral 
and cellular immune response and protect against the targeted infectious agent.  A good 
vaccine should contain epitopes that can induce both B-cell and T-cell immune 
responses. Besides induction of either B-cell or cytotoxic T-cell (CD8+) responses, the 
induction of helper T-cells (CD4+) is essential as it mediates the immune responses. For 
example, helper T cells help to activate cytotoxic T cells. Helper T cells can be divided 
into two subsets of effector cells based on their functional capabilities and the cytokines 
produced. The Th1 subset of CD4+ T helper cells secretes cytokines such as IFN-γ, IL-2 
and TNF-β and induces cell mediated immunity. The Th-2 cells produce cytokines such 
as IL-4 and IL-5 and help B cells to proliferate and stimulate a humoral response. The 
Th-1 cells promote the production of immunoglobulin IgG2a in mice and CD8+ 
cytotoxic T cells. To clear viruses from the infected cells, cytotoxic T cells (CD8+) seek 
out the infected cells and killing them. The Th-2 cells promote the production of IgG1 in 
mice.  
An ideal live attenuated vaccine is expected to be safe and provide protective 
immunity by inducing both humoral and cellular immunity. Protective immunity against 
viruses conferred by the LAV can be mediated by the secretion of neutralizing 
antibodies and the production of cytotoxic CD8+ cells. In this study, the isotypic 
distributions of IgG antibodies elicited by the mutant strains of EV-A71 (mutants 158, 
475, 486, 487, 5262 and PD) in response to immunization in mice were analysed. 
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(a)   EV-A71 (158)                 (475)                         (486)                             (487)          
    
 
(b)  EV-A71 (5262)                (PD)               Negative Control             Strain 41 
    
 
Figure 3.19: IgG1 and IgG2 responses elicited by EV-A71 Mutants and Controls. 
(a) Red bands correspond to IgG2a and IgG2b for EV-A71 mutants 158, 475, 486 and 
487. (b) EV-A71 mutants 5262, partial deletant 5’-NTR, negative control and wild type 
EV-A71. The IgG isotyping assays were repeated at least two separate times.  
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     (a) EV-A71 (158)                      (475)                                 (486)                       (487)           
 
    
 
(b)  EV-A71 (5262)     (PD)                        Negative Control        Strain 41 
    
Figure 3.20: IgG3, IgA and IgM responses elicited by EV-A71 Mutants and 
Controls. 
(a) Red bands correspond to IgG3, IgA and IgM for EV-A71 mutants 158, 475, 486 and 
487. (b) EV-A71 mutants 5262, partial deletant 5’-NTR, negative control and wild type 
EV-A71. The IgG isotyping assays were repeated at least two separate times. 
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Examination of the profiles of specific IgG subtypes in the mice antisera 
revealed that IgM, IgA, IgG2a and IgG2b antibodies were predominantly produced in 
pooled immune sera raised against the six EV-A71 mutants, and at levels comparable to 
that measured in the pooled immune sera obtained from mice immunized with the heat-
inactivated homologous EV-A71 whole virion. It was based on the observation of red 
bands from the mouse sub-type isotyping kit that showed red bands corresponded to 
isotypes IgM, IgA, IgG2a and IgG2b. This was consistent with previous studies that 
showed mouse infection with various viruses triggered an antiviral antibody response 
that was largely restricted to the IgG2a isotype (Coutelier et al., 1987).  In addition, 
among the four antibodies (IgG1, IgG2a, IgG2b, IgG3), it was reported that IgG2a 
delayed the onset and progression of lactate dehydrogenase-elevating virus (LDV) 
induced polio-encephalomyelitis more than the other subtypes. This suggested that the 
IgG2a predominance observed in many IgG antibody responses elicited by live viruses 
may potentially correspond to the selection of the best protection for the infected host 
(Markine-Goriaynoff and Coutelier, 2002). 
In contrast, the levels of IgG1 and IgG3 measured in pooled immune sera from 
mice immunized with the EV-A71 mutants were not significantly different from the 
levels measured in the negative control mice while those measured in the pooled 
immune sera from mice immunized with the heat-inactivated EV-A71 whole virion 
showed significantly more intense red bands corresponding to the IgG isotypes, 
respectively. The presence of the IgA in the antisera indicates the induction of mucosal 
immunity. Generally, IgG1 in mice is associated with a Th2 profile and IgM, IgA, IgG2 
and IgG3 are mainly associated with a Th1 profile (Banerjee et al., 2010). Altogether, 
these data indicate that the intraperitoneal administration of heat-inactivated EV-A71 
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mutants 158, 475, 486, 487, 5262 and PD and the homologous EV-A71 whole virion 
triggered a stronger Th1 response which is cell mediated immunity. 
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CHAPTER 4      
DISCUSSION 
Previous studies by Arita et al. (2005) showed that cynomolgus monkeys 
immunized with an EV-A71 (S1-3’) mutant strain still developed mild neurological 
symptoms, although there was reduced virulence. They had attempted to develop a live-
attenuated vaccine (LAV) against EV-A71 by introducing 3 mutations at nucleotides 
485, 486 and 475 in the EV-A71 genotype A genome which corresponded to the 
mutations present in Sabin 1, 2 and 3, respectively. However, the virus still caused 
tremors and was isolated from the spinal cord. Hence, this strain did not meet the criteria 
to be used as a LAV.  
Therefore, we examined EV-A71 sub-genotype B4, strain 41 (5865/Sin/000009) 
to generate attenuated EV-A71 strains. We genetically modified the EV-A71 virus by 
substituting nucleotides at positions 475, 486, and 487 based on the fact that these 
nucleotides are responsible for the neurovirulence of poliovirus Sabin strains 1, 2 and 3 
(Table 1.4). The virulence determinants of poliovirus and EV-A71 reported in previous 
studies served as references in this study to produce EV-A71 viruses that are highly 
attenuated. In addition, we also investigated if EV-A71 sub-genotype B4 has a different 
virulence determinant from the sub-genotype B1 (clinical isolate 237) (Yeh et al., 2011). 
The EV-A71 sub-genotype B4 virus was modified to carry a mutation at nucleotide 
position 158 to assess if the nucleotide is a common virulence determinant between the 
sub-genotypes B4 and B1 (Fig. 1.9).  
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Liu et al. (2014) found that there were nine amino acid substitutions (H22Q, 
P27S, N31S/D, E98K, E145G/Q, D164E, T240A/S, V249I, A289T) that were detected 
after aligning the VP1 sequences of fatal and mild EV-A71 strains of sub-genotype C4 
(Liu et al., 2014). As such, these residues maybe potential virulence determinants in 
VP1 and could convert mild EV-A71 cases into severe cases. The study was consistent 
with previous investigations by Chang et al. (2012) who observed that the E145Q 
substitution at the 5’-NTR was a common difference in the EV-A71 genome of mild and 
fatal cases of HFMD. Additionally, they also discovered that strains isolated from 
patients with fatal outcomes had greater substitutions in the 5’-NTR and IRES regions 
(Chang et al., 2012). This is to be expected as these regions were responsible for 
receptor binding and cap-independent translation of viral proteins. The position of a 
certain specific amino acid in the genome may have a profound significance on 
virulence. For example, it was reported that the presence of Asn at position 165 of VP2 
in Coxsackievirus B3 was responsible for a cardio virulent phenotype (Knowlton et al., 
1996). 
It remains to be investigated if there is a universal molecular determinant present 
in every EV-A71 fatal strain or whether every fatal strain differs in virulence 
determinant depending on their sub-genotype. An EV-A71 mutant bearing a long 
deletion in the 5’-NTR of the genome was also constructed. In addition, the single nt. 
difference between the fatal (strain 41) and non-fatal strain (strain 10) of EV-A71 (sub-
genotype B4) is examined for neuro-virulence by changing the nt. substitution at 
position 5262 in the EV-A71 viral genome (Singh et al., 2002). However, as exemplified 
by the human immunodeficiency virus, laboratory strains are sometimes so 
115 
 
phenotypically and genotypically distinct from those found in infected individuals that 
therapeutic or preventative measures effective against these laboratory strains do not 
always correlate with naturally circulating strains (Mascola et al., 1996).  
The virulence of the various mutated EV-A71 strains was evaluated in the 
Rhabdomyosarcoma (RD) cell culture by plaque assays, viral infectivity by tissue 
culture infectious dose (TCID50) determinations, real time Reverse-Transcriptase 
Polymerase Chain Reaction (RT-PCR) and detection of VP1 by immunoblotting as well 
as in vivo studies. The TCID50 for the EV-A71 wild type strain 41 and mutant virus titers 
were quantitatively determined. The lower the virulence of a mutant strain, the higher 
the TCID50 value. Analysis of the TCID50 values indicated that mutants 475 and strain 
PD required higher doses of viruses to cause cytopathic effects in 50% of the tissue 
culture. Thus, mutants 475, and PD may serve as potential LAV candidates for further 
evaluation by other tests in vitro. 
Subsequently, the number of plaques produced by the various EV-A71 mutant 
strains was evaluated in the RD cell culture by plaque assays. If the ability to form 
plaques is reduced, this would mean that viral growth is slower, thereby producing a 
lower PFU/ml value. For example, the mutant 487 (10 x104 PFU/mL) and mutant 5262 
showed a much reduced plaque number (1.8 x 105 PFU/mL) when compared to the 
positive control (EV-A71 wild type strain 41) with 5.0 x 107 PFU/mL. The least number 
of viral plaques were formed by the mutant 475 carrying SDM at position 475 (7.0 x 104 
PFU/mL) and the partial deletant (PD) (9.0 x 104 PFU/mL). 
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The ability of the various mutated EV-A71 strains to produce viral particles 
could be evaluated by detection of VP1 by immunoblotting with the monoclonal 
antibody directed against VP1. RD cells infected with the wild type EV-A71 strain 41 
demonstrated the largest amount of the VP1 protein detected as evident from a thick, 
single band with molecular weight (MW) of 32kDa. This band corresponds to the VP1 
monomer with an apparent MW of 32.7kDa.  Minimal amount of VP1 was detected in 
the mutant strain carrying the site specific mutation at position 475 and the partial 
deletant (PD) in the 5’-NTR.  
An additional approach such as determination of the viral RNA copy number 
would enable a better quantitative comparison of attenuation of the various mutant 
strains. The viral RNA copy number of the various EV-A71 mutant strains was 
evaluated after growing in the RD cell culture for 24 hours. RD cells infected with the 
wild type EV-A71 strain 41 gave the highest yield of viral RNA copy number (5.5 X 
103). As for EV-A71 mutant 475 and PD, minimal RNA copy no. was detected for both 
mutants at 1.02 X 102 and 1.05 X 102 viral RNA, respectively. This was consistent with 
results from plaque assays, TCID50, and immunoblotting. These two mutants appear to 
hold promise and will be subjected to further evaluation tests to assess whether they 
could serve as potential LAV strains. Amongst all the mutants being evaluated, mutant 
486 carrying SDM at position 486 (A486G) expressed the highest viral RNA copy 
number of 3.2 X 103 when compared to the wild type strain 41. Attenuated strains with 
low viral RNA copy number are possible good vaccine strains as they cannot replicate 
fast enough to yield high viral load and cause destruction of the tissue cells. Slow 
replication could infer that the cells could carry enough antigens to stimulate an immune 
response.  
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Previous studies have shown that the VP1 capsid protein of EV-A71 constitutes a 
potential subunit vaccine candidate by triggering the production of protective anti-EV-
A71 neutralizing antibodies in a murine model of infection (Chen et al., 2006; Chiu; et 
al., 2006).  Chang and co-workers (2015) discovered that a single amino acid variation 
in VP1 could lead to significant differences in the sensitivity of EV-A71 to neutralizing 
antibody responses. They also identified EV-A71 strains that could induce potent 
immunogenic and cross-neutralizing antibody responses against diverse EV-A71 strains. 
Furthermore, these neutralizing antibodies could protect neonatal mice from lethal dose 
challenge with various circulating EV-A71 viruses (Chang et al., 2015).  
In this study, two EV-A71 mutants, PD and 5262, successfully elicited high titers 
of neutralizing antibodies (1:32) against EV-A71. To a lesser extent, the 475, 486 and 
487-immunized mice produced neutralizing antibodies against the EV-A71 strain 41 
with a neutralizing antibody titer of 1:16 (Table 3.2). The levels of neutralizing 
antibodies obtained by the EV-A71 mutants were lower than the levels obtained by 
Chou et al. (2012) (1:640). This could be due to alum being as an adjuvant in their 
studies while Freund’s complete adjuvant was used in our investigation. In addition, an 
anti-EV-A71 neutralizing titre of 1:16 or higher is able to confer protection against 
HFMD (Zhu et al., 2014). As EV-A71 mutants PD (1:32) and 475 (1:16) had high 
neutralizing titers, they are potential LAVs to be developed further as they have low 
pathogenicity and high immunogenicity. As neutralizing response plays a protective role 
against viral infectivity, EV-A71-neutralizing antibodies elicited by EV-A71 mutants 
PD and 475 should be characterized based on their specificities and functional roles in 
the neutralization process. In addition, the immunogenicity studies could be repeated 
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with a different adjuvant and the genetic stability of these mutants has to be further 
investigated.  
An ideal LAV should be able to induce a protective antibody response as well as 
a cytotoxic T-cell response important for killing infected host cells. Such knowledge on 
the immune response to EV-A71 infection is crucial to the development of the LAV and 
special vaccination challenges presented by this virus. A previous study by Lidbury et 
al. (2000) showed that the antibody responses of irradiated virus-erythrocyte complex 
(IV-EC) and live virus-erythrocyte complex (LV-EC) vaccinated mice showed 
significantly elevated lung and serum IgG2a levels post live virus challenge, with no 
comparable increases in IgG1 levels compared to controls.  Their results suggested that 
protection from live influenza (H3N2) challenge after IV-EC or LV-EC vaccination was 
due to an IFN-mediated IgG2a response.   
This was consistent with our results as the IgG subtype analysis of EV-A71 
mutants 158, 475, 486, 487, 5262 and PD antisera demonstrated strong IgA, IgM, IgG2a 
and IgG2b specific antibody response and low IgG1 and IgG3 antibody responses which 
indicates a skewed Th1 immune response. There has been support in alternative vaccine 
approaches that induce a more Th1 skewed response. IgG titres detected by the antigen 
ELISA were lower than neutralization titres and this could possibly be due to high assay 
background and low sensitivity of the assay (Bielinska et al., 2008; Wille-Reece et al., 
2015). Bek and co-workers (2011) also surmised that the dosage of vaccine suspension 
administered and the type of adjuvant used could also account for the differing 
neutralizing and IgG titres.  
The results in a study by Visciano et al. (2012) showed that adjuvants are able to 
skew the immune response of HIV-VLPs toward a Th1 profile. Additionally, the role of 
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the adjuvant in the vaccine formulation may influence the IgG profile and this should 
not be discounted. Nevertheless, the results are desirable as an effective LAV should 
trigger both the humoral and cellular immune response. These observations suggest that 
EV-A71 mutants 158, 475, 486, 487, 5262 and PD contained B cell epitopes and the 
neutralizing antibodies elicited by these mutants belong to the IgM subtype. Production 
of large amounts of IgG2a and IgG2b by all the mutants and the wild type indicates 
good cellular immune responses and the presence of IgA points to a good mucosal 
response as well. 
Although a number of EV-A71 mutants with good in vivo passive protective 
potential have been identified, further studies could be performed to assess the genetic 
stability of the mutant strains. Reversion of the mutant strains will indicate if it is 
genetically stable or it will revert to the original nt. This can be performed by serial 
passaging and recovering the viral strain after a series of passaging. If the mutant 
reverts, this will be picked up during serial passages by sequencing of the whole viral 
genome. In addition, better attenuated mutants could be constructed by introducing 
multiple mutations into the attenuated EV-A71 mutant 475 or PD. With advances in 
molecular biology, novel approaches to viral attenuation can be further studied such as 
altered replication fidelity, codon deoptimization and microRNA-controlled LAVs. As 
high mutation rates often hinder the effectiveness of a LAV, altering the replication 
fidelity can attenuate the entire virus population, leading to population collapse without 
mutation of key immunogenic epitopes. miRNAs can be used to control the replication 
of RNA viruses, respectively. By controlling viral replication temporally, a strong, 
natural immune response can be elicited before the virus is eliminated (Lauring et al., 
2010). 
120 
 
As for codon deoptimization, synonymous codons can be substituted throughout 
a viral genome, hence preventing loss of immunogenicity and little risk of reversion to 
wild type. Studies on codon bias for viral replication and pathogenicity of poliovirus 
(PV) have been reported. Burns et al., (2006) replaced half of the total codons in the 
capsid region of Sabin type 2 oral polio vaccine strain with non-preferred synonymous 
codons. They discovered that synthesis and processing of viral proteins were unaffected 
but viral fitness was significantly reduced (Burns et al., 2006). In a later study (2009), 
they replaced natural capsid region codons with synonymous codons that had increased 
frequencies of CpG and UpA dinucleotides. They produced codon-deoptimised PVs that 
had significantly lower overall fitness as indicated by lower viral plaque number and 
virus yields (Burns et al., 2009). Also working with codon-deoptimized PVs, Mueller et 
al., (2006) used gene synthesis technology to introduce the largest possible number of 
rarely used synonymous codons in the capsid region of PV type 1 Mahoney. They found 
a significant decrease in replicative fitness and number of infectious viral progeny. 
There was also reduction of genome translation and virus-particle infectivity of up to 
1,000-fold as compared to the wild type (Mueller et al., 2006). Interestingly, both Burns 
et al., (2006) and Mueller et al., (2006) discovered that the deoptimised viruses 
remained attenuated after repeated cell passages and hence, were genetically stable with 
minimal risk of reversion.  
It is well known that some virulent strains of EV-A71 are capable of causing 
paralytic disease indistinguishable from poliomyelitis caused by the poliovirus. Virulent 
strains of EV-A71 are referred to as the new polio as it is neurotropic. The EV-A71 
strains had 46% amino acid identity with the polioviral P1 capsid region and 55% with 
the entire polyprotein (Brown and Pallansch, 1995). In addition, EV-A71 and PV share 
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high sequence homology especially in the 5’-NTR region hence, the codon 
deoptimisation research on PV reported in previous studies could serve as references to 
produce EV-A71 viruses that are highly attenuated. 
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CHAPTER 5      
CONCLUSION 
The Hand, Foot and Mouth Disease is caused by a group of Enteroviruses such 
as Enterovirus 71 (EV-A71) and Coxsackievirus CVA5, CVA6, CVA10, and CV-A16. 
Mild symptoms of EV-A71 infection in children range from high fever, vomiting, rashes 
and ulcers in the mouth, commonly affecting children and infants. EV-A71 can produce 
more severe symptoms such as brainstem and cerebellar encephalitis, leading up to 
cardiopulmonary failure and death. The lack of vaccines and antiviral drugs against EV-
A71 highlights the urgency of developing vaccines to prevent and antiviral agents to 
treat EV-A71 infections. 
The molecular basis of virulence in EV-A71 is still uncertain. It remains to be 
investigated if there is a universal molecular determinant present in every EV-A71 fatal 
strain or whether every fatal strain differs in virulence determinant depending on their 
sub-genotype. In this study, the EV-A71 virus was genetically modified by substituting 
nucleotides at positions 158, 475, 486, and 487 based on the neuro-virulence of 
poliovirus Sabin strains 1, 2 and 3. We also investigated if the single nucleotide 
difference in strain 41 (5865/Sin/000009) between the fatal and the non-fatal strain 
(strain 10) was responsible for neurovirulence by introducing a nucleotide substitution at 
position 5262 in the EV-A71 genome. Another mutant strain was also constructed 
through partial deletion of the 5’-NTR region in the EV-A71 genome.   
In conclusion, EV-A71 mutant 158 was not the most attenuated as it still 
produced more RNA, plaques and VP1 than mutants 5262, 487, 475 and the partial 
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deletant PD. Therefore, it is not the single neuro-virulence determinant for strain 41 
which belongs to genotype B4 when compared to EV-A71 genotype B1 studied by Yeh 
et al. (2011). Results support the hypothesis that every EV-A71 genotype or sub-
genotype carries a different virulence determinant. The single site mutation created by 
introducing a nt. change at position 5262 did not completely eliminate the ability to 
replicate and form plaques. There was some attenuation by SDM at this site but the 
effect of attenuation at this site was less than the effects brought about by introducing 
SDM into sites 475, 487 and the partial deletion. The partial deletant may be the most 
stable mutant genetically as it demonstrated high immunogenicity (neutralizing titre of 
1:32) and low pathogenicity and hence, could be a good potential LAV candidate for 
further studies. In addition, intraperitoneal administration of the heat-inactivated EV-
A71 mutants 158, 475, 486, 487, 5262 and PD and the homologous EV-A71 whole 
virion triggered a skewed Th1 response.  
Further studies should be conducted to investigate the stability of the mutations 
created by SDM in each mutant. A strain that is genetically highly stable and does not 
revert easily would thereby make a better LAV for EV-A71. Compared to conventional 
vaccines, the LAV is cheaper to produce, induces excellent immunogenicity and confers 
live-long immunity. LAV is preferred over the inactivated EV-A71 vaccine as it can 
elicit both humoral and cellular immunity, alongside the innate and adaptive immunity. 
In view of the rising concerns over EV-A71 infections with resulting fatalities in the 
large scale outbreaks in the Asia Pacific region, the results obtained in this study 
demonstrated potential LAV candidates against EV-A71 infections. 
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APPENDICES 
Appendix I  Reagents for growth media 
DMEM growth medium 
2X DMEM 500 ml 
FBS 100 ml 
Penicillin/streptomycin 10 ml 
NEAA 10 ml 
L-glutamine 10 ml 
MiliQ H2O 370 ml 
The media was stored at 4°C until use. 
 
DMEM maintenance medium 
2X DMEM 500 ml 
FBS 20 ml 
Penicillin/streptomycin 10 ml 
NEAA 10 ml 
L-glutamine 10 ml 
MiliQ H2O 450 ml 
The media was stored at 4°C until use. 
 
Plaque medium (1.2% w/v carboxymethylcellulose) 
2X DMEM 500 ml 
FBS 20 ml 
Penicillin/streptomycin 10 ml 
NEAA 10 ml 
L-glutamine 10 ml 
MiliQ H2O 450 ml 
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Carboxymethylcellulose 12 g 
The media was stored at 4°C until use. 
 
MEM Freezing Media 
1x MEM 89.5 ml 
1x Penicillin/Streptomycin 1.0 ml 
Fetal Calf Serum (FCS) 5.0 ml 
1.0 M HEPES Buffer 2.0 ml 
7% Sodium Bicarbonate 1.5 ml 
Dimethyl sulphoxide (DMSO) 1.0 ml 
The media was prepared fresh before carrying out the procedure for cell freezing. 
DMSO was protected from light and stored at room temperature. 
 
Media for Bacterial Culture 
LB (Luria-Bertani) Medium, per liter (Miller, 1972) 
NaCl 10 g 
Trytone 10 g 
Yeast extract 5 g 
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Appendix II Sequencing Results 
 
Mutant A158T 
 
Mutant C475T 
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Mutant A486G 
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     Mutant G487A 
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          Mutant A5262G 
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5’-NTR Partial Deletant Mutant (475-485) 
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Appendix III   Real Time RT-PCR  
Standard Curve for Interpolation of Unknown RNA Copy Number  
 
Standards: RNA of different concentrations from 10-1 to 10-6 uM. 
Calculations of viral RNA copy number were based on interpolation of the standard 
curve. 
 
 
 
 
 
 
 
 
Log Concentration 
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Appendix IV Materials for SDS-PAGE 
 
 
6x SDS Gel Loading Dye 
 
Tris-HCl    0.35 M 
SDS     10.28 % 
Glycerol    36.0 % 
Dithiothreitol (DTT)   0.6 M 
Bromophenol Blue   0.012 % 
 
The pH was adjusted to 6.8 and stored at -20oC until used. 
 
 
SDS Running Buffer 
 
Tris-BASE    25 mM 
Glycine    192 mM 
SDS       0.1 % 
 
The pH was adjusted to 8.3 and the volume was prepared up to 10 L with distilled water. 
 
SDS Staining Solution 
Ethanol    40 % 
Acetic acid    10 % 
Coomassie Brilliant Blue  0.1 % 
Distilled water   50 % 
The mixture was stored at 4oC until used. 
 
SDS Destaining Solution 
Ethanol    40 % 
Acetic acid    10 % 
Distilled water   50 % 
The mixture was stored at 4oC until used. 
 
146 
 
Appendix V  Materials for Western Blot 
 
Western Transfer Buffer 
Tris-HCL    3.03 g 
Glycine    1.44 g 
Methanol    200 ml 
The volume was prepared up to 1 L with distilled water and stored at 4oC until used. 
 
Western Blocking Buffer 
Tris-HCL    20 mM 
NaCl     150 mM 
Tween 20    0.05 % 
Bovine Serum Albumin   1 % 
 
Western Washing Buffer 
Tris-HCL    20 mM 
NaCl     150 mM 
Tween 20     0.05 % 
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APPENDIX VI TCID50 Assay 
Determination of infective dose (TCID50) 
TCID50 was calculated using the Reed and Muench formula. 
1. The cumulative number of infected wells was obtained by adding all the wells which 
showed CPE at every dilution. (E.g. at dilution 10-5, 2 wells showed CPE. At dilution 10-
4, 3 wells showed CPE. Hence, the total number of wells which showed CPE up to 
dilution factor 10-4 was 2 + 3 = 5) 
2. The cumulative number of wells which were not infected with the virus was obtained 
by subtracting the number of wells which showed CPE from the number of wells 
inoculated. (E.g. at dilution 10-4, 1 well did not show CPE. At dilution 10-5, 2 wells did 
not show CPE. Hence, the total number of wells which did not show CPE up to the 
dilution factor 10-5 was 1 + 2 = 3). 
3. The percentage of infectivity was calculated by dividing the total sum of the wells 
which showed CPE and those did not show CPE by the cumulative number of wells 
which showed CPE. (E.g. at dilution 10-4, 5/5+1 = 0.83 = 83%). 
4. TCID50 end point calculation: The negative logarithm of the dilution factor which was 
the closest to 50% was -4. Hence, the TCID50 end point = -4.0 + (0.7) = -4.7. Therefore, 
the log of TCID50 end point or titer = 10 X 10
4.7 =  
5. TCID50 =   (% wells infected at dilution next above 50%) – (50%)  
(% wells infected at dilution next above 50%) – (% wells infected at dilution next below 50%) 
  
Whereby h = dilution factor 
 Dilution of original suspension that is equal to the TCID50 = 10 
(log dilution next above 50%) – (I x 
log h)  
Since the wells were inoculated with 100uL virus suspension, 1mL of the virus 
suspension will contain ten times the reciprocal of the calculated dilution above.  
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